Methods, apparatuses, and systems for improving microbial preservation yield through rescue and serial passage of preserved cells

A multi-step preservation method using freeze-drying, vitrification, and controlled drying enhances microbial survival rates by up to 30%, addressing storage-related damage and maintaining microbial viability for use in synthetic ensembles and products.

JP2024156909AInactive Publication Date: 2024-11-06NATIVE MICROBIALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024129950
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-02-28
Filing Date
2024-08-06
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods for preserving microbial viability during storage often result in reduced survival rates due to factors like freezing-induced dehydration and phase transformations, leading to damage and instability of biologically active substances.

Method used

A method involving multiple preservation challenges, including freeze-drying, vitrification, evaporative drying, and foam formation, followed by stabilization at ambient temperatures to enhance microbial survival, using protective agents and controlled drying processes to maintain viability and functionality.

Benefits of technology

The method significantly improves microbial survival rates by up to 30% through sequential challenges, ensuring stability and functionality of microorganisms during storage, allowing them to be used in synthetic ensembles and living microbial products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156909000001_ABST
    Figure 2024156909000001_ABST
Patent Text Reader

Abstract

To provide methods of improving microbe viability after preservation, comprising subjecting a population of target microbial cells to one or more preservation challenges and preparing a product using the population of preserved viability-enhanced microbial cells produced from the methods.SOLUTION: Provided is a method of improving microbe viability after preservation, comprising: a. subjecting a population of target microbial cells to a first preservation challenge to provide a population of challenged microbial cells; b. harvesting viable challenged microbial cells from the population of challenged microbial cells; c. preserving the viable challenged microbial cells to provide a population of preserved viability-enhanced microbial cells; and d. preparing a product using the population of preserved viability-enhanced microbial cells.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 812,232, filed February 28, 2019, the contents of which are incorporated by reference in their entirety.

[0002] Description of electronically transmitted text files The sequence listing associated with this application is provided in text format instead of paper and is incorporated herein by reference. The name of the text file containing the sequence listing is ASBI-017_01WO_ST25.txt. The text file, created on February 28, 2020, is 8kb and has been submitted electronically via EFS-Web. [Background technology]

[0003] Microorganisms coexist in nature as communities, but engage in a variety of interactions that result in both cooperation and competition between individual community members. Advances in microbial ecology have revealed high levels of species diversity and complexity in most communities. Microorganisms are ubiquitous in the environment and live in various ecosystems within the biosphere. Individual microorganisms and their respective communities play unique roles in the environment, for example, marine fractions (both deep and surface), soil, and animal tissues, including human tissues. Summary of the Invention

[0004] In some embodiments, the present disclosure provides a method of improving viability of a microorganism after storage, comprising: subjecting a population of target microbial cells to an initial storage challenge to obtain a population of challenge microbial cells; harvesting viable challenge microbial cells from the population of challenge microbial cells; preserving the viable challenge microbial cells to obtain a population of preserved viability-enhanced microbial cells; and preparing a product using the population of preserved viability-enhanced microbial cells.

[0005] In some embodiments, the first preservation challenge comprises one of freeze-drying, lyophilization, cryopreservation, evaporative preservation, foam preservation, vitrification, glass stabilization, vapor preservation, spray drying, adsorption drying, extrusion, or fluid bed drying. In some embodiments, the preservation of the viable challenge cells comprises freeze-drying, lyophilization, cryopreservation, evaporative preservation, foam preservation, vitrification, glass stabilization, vapor preservation, spray drying, adsorption drying, extrusion drying, or fluid bed drying. In some embodiments, the population of challenge cells is subjected to at least one additional preservation challenge.

[0006] In some embodiments, the disclosure provides a method for viability enhancement and preservation of microorganisms, the method comprising: subjecting a population of target microbial cells to a first preservation challenge to obtain a first population of challenge microbial cells; harvesting viable challenge microorganisms from the first population of challenge microbial cells to obtain a first population of viable challenge microbial cells; subjecting the first population of viable challenge microbial cells to a second preservation challenge to obtain a second population of challenge microbial cells; harvesting viable challenge microorganisms from the second population of challenge microbial cells to obtain a second population of viable challenge microbial cells; preserving the second population of viable challenge microbial cells to obtain a preserved population of viable microbial cells; and preparing a product using the preserved population of viable microbial cells.

[0007] In some embodiments, the first and second preservation challenges are of the same challenge type. In some embodiments, the first and second preservation challenges are of different challenge types. In some embodiments, the first and second preservation challenges are selected from the combinations listed in Table 1. In some embodiments, the second population of challenged cells is subjected to at least one additional preservation challenge. In some embodiments, preservation of the second viable challenge cell population includes freeze-drying, lyophilization, cryopreservation, preservation by evaporation, preservation by foam formation, vitrification, stabilization by glass formation, preservation by evaporation, spray drying, adsorption drying, extrusion drying, or fluid bed drying.

[0008] In some embodiments, the population of target microbial cells comprises bacteria of Clostridium spp., Succinivibrio spp., Butyrivibio spp., Bacillus spp., Lactobacillus spp., Prevotella spp., Syntrophococcus spp., or Ruminococcus spp. In some embodiments, the population of target microbial cells comprises fungi of Caecomyces spp., Pichia spp., Orpinomyces spp., or Piromyces spp. In some embodiments, the population of target microbial cells comprises species of the Lachnospiraceae family.

[0009] In some embodiments, Clostridium spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6; Succinivibrio spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:11; Pichia spp. comprises an ITS sequence that comprises at least 97% sequence identity to SEQ ID NO:2; Bacillus spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:4; Lactobacillus spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9; Prevotella spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:10; or a species of the Lachnospiraceae family comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:12.

[0010] In some embodiments, the population of target microbial cells includes bacteria of Ruminococcus bovis, bacteria of Succinivibrio dextrinosolvens, or fungi of Caecomyces spp. In some embodiments, the population of target microbial cells includes bacteria of Clostridium butyricum, bacteria of Pichia These include the fungus Butyrivibio fibrosolvens, the bacteria Ruminococcus bovis, or the bacteria Succinivibrio dextrinosolvens.

[0011] In some embodiments, the disclosure provides a product prepared by the method described herein, comprising a population of preserved viability-enhanced microbial cells. In some embodiments, the preserved population of viability-enhanced microbial cells comprises Clostridium spp. bacteria, Succinivibrio spp. bacteria, Caecomyces spp. fungi, Pichia spp. fungi, Butyrivibio spp. bacteria, Orpinomyces spp. fungi, Piromyces spp. fungi, Bacillus spp. bacteria, Lactobacillus spp. bacteria, Prevotella spp. bacteria, Syntrophococcus spp. bacteria, Ruminococcus spp. bacteria, or species of the Lachnospiraceae family. In some embodiments, Clostridium spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6; Succinivibrio spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:11; Pichia spp. comprises an ITS sequence that comprises at least 97% sequence identity to SEQ ID NO:2; Bacillus spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:4; Lactobacillus spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9; Prevotella spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:10; or a species of the Lachnospiraceae family comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:12. In certain embodiments, for example, the following are provided: (Item 1) Methods to improve the survival rate of microorganisms after storage include: a. subjecting a population of target microbial cells to an initial storage challenge to obtain a population of challenge microbial cells; b. harvesting viable challenge microbial cells from said population of challenge microbial cells; c. storing the viable challenge microbial cells to obtain a population of stored viability-enhanced microbial cells; and d. preparing a product using said population of preserved viability-enhanced microbial cells; The method comprising: (Item 2) 2. The method of claim 1, wherein the first preservation challenge comprises freeze-drying, lyophilization, cryopreservation, evaporative preservation, foam preservation, vitrification, glass stabilization, evaporative preservation, spray drying, adsorption drying, extrusion, or fluidized bed drying. (Item 3) 3. The method of claim 1 or claim 2, wherein preservation of the viable challenge cells comprises freeze-drying, lyophilization, cryopreservation, evaporative preservation, foam preservation, vitrification, glass stabilization, evaporative preservation, spray drying, adsorption drying, extrusion drying, or fluid bed drying. (Item 4) 4. The method of any one of items 1 to 3, further comprising subjecting said population of challenged cells to at least one additional preservation challenge. (Item 5) 1. A method for enhancing the viability and preservation of microorganisms, said method comprising: a. subjecting a population of target microbial cells to an initial storage challenge to obtain an initial population of challenge microbial cells; b. harvesting a viable challenge microorganism from said first population of challenge microbial cells to obtain a first population of viable challenge microbial cells; c. subjecting said first population of viable challenge microbial cells to a second storage challenge to obtain a second population of challenge microbial cells; d. harvesting a viable challenge microorganism from said second population of challenge microbial cells to obtain a second population of viable challenge microbial cells; e. storing said second population of viable challenge microbial cells to obtain a stored population of viability-enhanced microbial cells; and f. preparing a product using said population of preserved viability-enhanced microbial cells; The method comprising: (Item 6) 6. The method of claim 5, wherein the first stored challenge and the second stored challenge are of the same challenge type. (Item 7) 6. The method of claim 5, wherein the first stored challenge and the second stored challenge are of different challenge types. (Item 8) 6. The method of claim 5, wherein the first and second storage challenges are selected from the combinations listed in Table 1. (Item 9) The method of any one of items 5 to 8, further comprising subjecting said second population of challenged cells to at least one additional storage challenge. (Item 10) 10. The method of any one of items 5 to 9, wherein preservation of the second viable challenge cell population comprises freeze-drying, lyophilization, cryopreservation, evaporative preservation, foam preservation, vitrification, vitrification stabilization, evaporative preservation, spray drying, adsorption drying, extrusion drying, or fluidized bed drying. (Item 11) 11. The method according to any one of items 1 to 10, wherein said population of target microbial cells comprises bacteria of Clostridium spp., Succinivibrio spp., Butyrivibio spp., Bacillus spp., Lactobacillus spp., Prevotella spp., Syntrophococcus spp. or Ruminococcus spp. (Item 12) The population of target microbial cells is selected from the group consisting of fungi of Caecomyces spp., Pichia 11. The method according to any one of items 1 to 10, comprising a fungus of Orpinomyces spp., a fungus of Orpinomyces spp., or a fungus of Piromyces spp. (Item 13) 11. The method according to any one of items 1 to 10, wherein said population of target microbial cells comprises a species of the family Lachnospiraceae. (Item 14) a. the Clostridium spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6; b. the Succinivibrio spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:11; c. the Pichia spp. comprises an ITS sequence that comprises at least 97% sequence identity to SEQ ID NO:2; d. the Bacillus spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:4; e. the Lactobacillus spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9; f. the Prevotella spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO: 10; or g. The method of any one of items 11 to 13, wherein said species of the family Lachnospiraceae comprises a 16S rRNA sequence comprising at least 97% sequence identity to SEQ ID NO: 12. (Item 15) 11. The method according to any one of items 1 to 10, wherein said population of target microbial cells comprises bacteria of Ruminococcus bovis, bacteria of Succinivibrio dextrinosolvens, or fungi of Caecomyces spp. (Item 16) 11. The method according to any one of items 1 to 10, wherein said population of target microbial cells comprises bacteria of Clostridium butyricum, fungi of Pichia kudriazevii, bacteria of Butyrivibio fibrosolvens, bacteria of Ruminococcus bovis, or bacteria of Succinivibrio dextrinosolvens. (Item 17) 17. A product prepared by the method of any one of items 1 to 16, comprising a population of preserved viability-enhanced microbial cells. (Item 18) 18. The product according to item 17, wherein said population of preserved viability-enhancing microbial cells comprises Clostridium spp. bacteria, Succinivibrio spp. bacteria, Caecomyces spp. bacteria, Pichia spp. fungi, a Butyrivibio spp. bacteria, Orpinomyces spp. fungi, Piromyces spp. fungi, Bacillus spp. bacteria, Lactobacillus spp. bacteria, Prevotella spp. bacteria, Syntrophococcus spp. bacteria, Ruminococcus spp. bacteria, or species of the Lachnospiraceae family. (Item 19) a. the Clostridium spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6; b. the Succinivibrio spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:11; c. the Pichia spp. comprises an ITS sequence that comprises at least 97% sequence identity to SEQ ID NO:2; d. the Bacillus spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:4; e. the Lactobacillus spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9; or f. the Prevotella spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO: 10; or g. The product of item 18, wherein the species of the family Lachnospiraceae comprises a 16S rRNA sequence comprising at least 97% sequence identity to SEQ ID NO:12. [Brief description of the drawings]

[0012] [Figure 1] A process flow diagram illustrating a method according to the present disclosure is provided. [Diagram 2] 1 provides a challenge / rescue survival improvement flow according to one embodiment of the present disclosure. [Diagram 3] Examples of the results of applying the disclosed methods to two different microorganisms are provided. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] overview According to some embodiments of the present disclosure, methods, devices, and systems for rescue / serial challenge survival improvement, including improved stabilization / preservation yield of microorganisms, occur through rescue and serial challenge / passage of cells. By way of non-limiting example, such methods are disclosed that can be used in forming synthetic ensembles, synthetic bioensembles, and / or live microbial products. In some embodiments, such synthetic ensembles contain and / or include one or more stabilized and / or preserved microorganisms, such as one or more microorganisms disclosed in one or more of U.S. Patent Application Publication Nos. 2018 / 0310592, 2018 / 0333443, and 2018 / 0223325 (each of which is expressly incorporated herein by reference for all purposes).

[0014] According to some embodiments of the present disclosure, methods, devices, and systems for rescue / serial challenge survival improvement, including improved stabilized / preserved yield of microorganisms, occur through rescue and serial challenge / passage of cells. By way of non-limiting example, such methods are disclosed that can be used in forming synthetic ensembles, synthetic bioensembles, and / or live microbial products. In some embodiments, such synthetic ensembles contain and / or include one or more stabilized and / or preserved microorganisms.

[0015] According to some embodiments, a target strain is identified. Then, once the target strain is identified, an initial culture of the strain is grown and then the cells are initially harvested from the culture. Once harvested, a pre-challenge baseline can be set / established and / or an initial viability test can be performed. After harvesting, the cells are prepared for challenge, for example, by combining with a preservation solution. Exemplary preservation solutions can include, by way of non-limiting example, intracellular protectants (e.g., sugars, particularly non-reducing sugars; sugar alcohols, such as sorbitol), pH buffers (e.g., monosodium glutamate, monopotassium phosphate, dipotassium phosphate, etc.), membrane protectants (e.g., polyvinylpyrrolidone K-15, etc.), as well as components that aid in preservation (e.g., sucrose for glass formation, where applicable) and quality control (e.g., redox indicators, such as resazurin for use with anaerobic microorganisms, etc.). Once the cells are prepared for challenge, an initial preservation challenge is performed. Examples of preservation / stabilization challenges may include, but are not limited to, freeze-drying / lyophilization, cryopreservation, evaporative preservation, foam preservation, vitrification / glass-formation stabilization, vapor preservation, spray drying, adsorption drying, extrusion, or fluid bed drying. According to some embodiments, there may be multiple challenges prior to incorporation and / or formation into the final product. In some embodiments, the challenge(s) may be the same as the final preservation / stabilization, while in other embodiments, there may be multiple types of challenges used, each of which may be the same or different from the final preservation. For example, if the PBV is the final stabilization / preservation step, the challenge(s) may include a PBV challenge, and in some embodiments, may also include a cryopreservation challenge in addition to the PBV challenge and the final PBV process.

[0016] Once the initial conservation challenge has been performed, a challenge strain / preserved cells are prepared and grown in rescue culture, and cells are harvested from the rescue culture and tested for viability. The challenge strain can be prepared and subjected to one or more additional challenges (which can be the same or different from the previous challenge(s) and / or final preservation / stabilization, as described above). Once the challenge is complete, viable challenge cells are harvested from the rescue culture for preservation / stabilization, and the harvested challenge cells are preserved / stabilized to obtain viability-enhanced cells. The viability-enhanced cells can then be used for and / or incorporated into a final product, such as an ensemble, a live microbial feed additive, a live microbial feed supplement, etc.

[0017] definition As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, the term "organism type" is intended to mean a single organism type or multiple organism types. In another example, the term "environmental parameter" may mean a single environmental parameter or multiple environmental parameters, such that the indefinite article "a" or "an" does not preclude the possibility that multiple environmental parameters are present, unless the context clearly requires that only one environmental parameter is present.

[0018] Throughout this specification, references to "one embodiment," "an embodiment," "one aspect," "one aspect," "one implementation," or "an implementation" mean that a particular feature, structure, or characteristic described in connection with an embodiment is included in at least one embodiment of the disclosure. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular elements, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[0019] As used herein, in certain embodiments, the term "about" or "approximately" when preceding a numerical value indicates a range of the value plus or minus 10%. When a range of values ​​is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit, between the upper and lower limits of that range and any other stated value or intervening value in the stated range, is encompassed within the disclosure, unless the context clearly indicates otherwise. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges, which are also encompassed within the disclosure, subject to any limits specifically excluded in a given range. When a stated range includes one or both limits, ranges excluding either or both of those included limits are also included in the disclosure.

[0020] As used herein, "carrier", "acceptable carrier", or "pharmaceutical carrier" refers to a diluent, adjuvant, excipient, or vehicle used with or in a microbial ensemble. Such carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water or aqueous solutions, saline, and aqueous dextrose and glycerol solutions are preferably used as carriers, in some embodiments, as injectable solutions. Alternatively, the carrier can be a solid dosage form alone, including, but not limited to, one or more of binders (in the case of compressed pills), lubricants, encapsulating agents, flavoring agents, and coloring agents. The choice of carrier can be selected with regard to the intended route of administration and standard pharmaceutical practice. See Hardee and Baggo (1998. Development and Formulation of Veterinary Dosage Forms. 2nd Ed. CRC Press. 504 pg.); EW Martin (1970. Remington's Pharmaceutical Sciences. 17th Ed. Mack Pub. Co.); and Blaser et al. (U.S. Patent Publication No. US20110280840A1), each of which is expressly incorporated by reference herein in its entirety.

[0021] The terms "microorganism" and "microbe" are used interchangeably herein and refer to any microorganism that is of the domains Bacteria, Eukaryotes, or Archaea. Types of microorganisms include, but are not limited to, bacteria (e.g., mycoplasma, cocci, bacilli, rickettsia, spirillum), fungi (e.g., filamentous fungi, yeasts), nematodes, protozoa, archaea, algae, dinoflagellates, viruses (e.g., bacteriophages), viroids, and / or combinations thereof. A strain of organism is a sub-taxon of an organism type, and can be, for example, a species, subspecies, subtype, genetic variant, pathotype, or serotype of a particular microorganism.

[0022] As used herein, "spore"(s) refers to structures produced by bacteria and fungi that are suitable for survival and dispersal. Although spores are generally characterized as dormant structures, spores are capable of differentiation through the process of germination. Germination is the differentiation of a spore into a vegetative cell capable of metabolic activity, growth, and reproduction. Germination of a single spore results in a single fungal or bacterial vegetative cell. Fungal spores are the unit of asexual reproduction and in some cases are structures necessary for the fungal life cycle. Bacterial spores are structures for survival conditions that may normally be non-conductive for the survival or growth of vegetative cells. As used herein, "microbial composition" refers to a composition comprising one or more microorganisms of the present disclosure, which in some embodiments are administered to an animal of the present disclosure.

[0023] As used herein, an "individual isolate" should be taken to mean a composition or culture that contains a predominance of a single genus, species, or strain of a microorganism after separation from one or more other microorganisms. The phrase should not be taken to indicate the extent to which the microorganism has been separated or purified. However, an "individual isolate" may contain substantially only one genus, species, or strain of a microorganism.

[0024] As used herein, "microbiota" refers to the collection of microorganisms that inhabit the digestive or gastrointestinal tract of an animal (including the rumen if the animal is a ruminant) and the physical environment of the microorganisms (i.e., the microbiota has a biological and physical component). The microbiota is fluid and may be modulated by numerous natural and artificial conditions (e.g., dietary changes, disease, antimicrobial agents, influx of additional microorganisms, etc.). Modulation of the ruminal microbiota that can be achieved through administration of the compositions of the present disclosure can take the form of: (a) an increase or decrease in a particular family, genera, species, or functional category of microorganisms (i.e., a change in the biological component of the ruminal microbiota), and / or (b) an increase or decrease in volatile fatty acids in the rumen, an increase or decrease in ruminal pH, or an increase or decrease in any other physical parameter important for ruminal health (i.e., a change in the abiotic components of the ruminal microbiota). As used herein, "probiotic" refers to a substantially pure microorganism (i.e., a single isolate) or a mixture of desired microorganisms, and may also include any additional components that can be administered to a mammal to restore the microflora. The probiotic or microbial inoculant composition of the present invention may be administered with an agent that allows the microorganism to survive in the environment of the digestive tract, i.e., tolerating and growing at low pH in the gastrointestinal environment. In some embodiments, the composition (e.g., microbial composition) is, in some aspects, a probiotic.

[0025] The term "growth medium" as used herein is any medium suitable for supporting the growth of microorganisms. By way of example, the medium may be natural or artificial, including gastrin-supplemented agar, LB medium, serum, and tissue culture gel. It should be understood that the medium may be used alone or in combination with one or more other media. It may also be used with or without the addition of exogenous nutrients. The medium may be amended or enriched with additional compounds or components, such as components that may aid in the interaction and / or selection of specific groups of microorganisms. For example, antibiotics (e.g., penicillin) or antibiotics (e.g., quaternary ammonium salts and oxidizing agents) may be present, and / or physical conditions (e.g., salinity, nutrients (e.g., organic and inorganic minerals (e.g., phosphorus, nitrogen salts, ammonia, potassium, and trace elements such as cobalt and magnesium), pH, and / or temperature) may be amended.

[0026] As used herein, "improved" should be broadly construed to encompass an improvement in a characteristic of interest compared to a control group or compared to a known average amount associated with the characteristic in question. For example, "improved" milk production associated with the application of the beneficial microorganisms or ensembles of the present disclosure can be demonstrated by comparing milk produced by ungulates treated with the microorganisms taught herein to milk produced by untreated ungulates. In the present disclosure, "improved" does not necessarily require that the data be statistically significant (i.e., p<0.05); rather, a quantifiable difference indicating that one value (e.g., the average treatment value) is different from another value (e.g., the average control value) may be increased to an "improved" level.

[0027] As used herein, terms such as "inhibition and suppression" should not be construed as requiring complete inhibition or suppression, although this may be desirable in some embodiments. As used herein, the term "marker" or "unique marker" is an indicator of a unique microbial type, microbial strain, or microbial strain activity. Markers can be measured in biological samples and include, but are not limited to, nucleic acid-based markers, such as ribosomal RNA genes, peptide or protein-based markers, and / or metabolite or other small molecule markers.

[0028] As used herein, the term "molecular marker" or "genetic marker" refers to an indicator used in a method for visualizing differences in the characteristics of nucleic acid sequences. Examples of such indicators are restriction fragment length polymorphism (RFLP) markers, amplified fragment length polymorphism (AFLP) markers, single nucleotide polymorphisms (SNPs), insertion mutations, microsatellite markers (SSRs), sequence characteristic amplified regions (SCARs), cleaved amplified polymorphic sequences (CAPS) markers, or isozyme markers, or combinations of markers described herein that define specific genes and chromosomal locations. Markers further include polynucleotide sequences encoding 16S or 18S rRNA, and internal transcribed spacer (ITS) sequences, which are sequences found between small and large subunit rRNA genes that have proven useful, particularly in elucidating relationships or distinctions when compared to each other. Mapping molecular markers to the vicinity of alleles is a procedure that can be performed by an average person skilled in molecular biology techniques.

[0029] As used herein, the term "trait" refers to a characteristic or phenotype. For example, in the context of some embodiments of the present disclosure, the amount of milk fat produced is related to the amount of triglycerides, triacylglycerides, diacylglycerides, monoacylglycerides, phospholipids, cholesterol, glycolipids, and fatty acids present in milk. Desirable traits may also include other milk characteristics, including, but not limited to, the predominance of short-chain fatty acids, medium-chain fatty acids, and long-chain fatty acids; the amount of carbohydrates such as lactose, glucose, galactose, and other oligosaccharides; the amount of protein such as casein and whey; the amount of vitamins, minerals, milk yield / volume; reduced methane emissions or fertilizer; improved efficiency of nitrogen utilization; improved dry matter intake; improved feeding efficiency and digestibility; increased degradation of cellulose, lignin, and hemicellulose; and increased ruminal concentration of fatty acids such as acetate, propionate, and butyrate.

[0030] A trait may be inherited dominantly or recessively, or partially or incompletely dominant. A trait may be monogenic (i.e., determined by a single locus) or polygenic (i.e., determined by multiple loci), or may also result from the interaction of one or more genes with the environment. In the context of this disclosure, a trait may also result from the interaction of one or more mammalian genes and one or more microbial genes.

[0031] As used herein, the term "homozygous" refers to a genetic condition that exists when two identical alleles are present at a particular locus, but are located separately on corresponding pairs of homologous chromosomes in a cell of a diploid organism. Conversely, as used herein, the term "heterozygous" refers to a genetic condition that exists when two different alleles are present at a particular locus, but are located separately on corresponding pairs of homologous chromosomes in a cell of a diploid organism.

[0032] As used herein, the term "phenotype" refers to the observable characteristics of an individual cell, cell culture, organism (e.g., ruminants), or group of organisms that result from the interaction between the individual's genetic makeup (i.e., genotype) and the environment.

[0033] As used herein, the term "chimeric" or "recombinant" when describing a nucleic acid or protein sequence refers to a nucleic acid or protein sequence that links at least two heterologous polynucleotides, or two heterologous polypeptides, into a single polymer, or that rearranges one or more elements of at least one naturally occurring nucleic acid or protein sequence. For example, the term "recombinant" can refer to the artificial combination of two otherwise separated segments of a sequence, e.g., by chemical synthesis or by the manipulation of isolated segments of nucleic acids by genetic engineering techniques.

[0034] As used herein, a "synthetic nucleotide sequence" or "synthetic polynucleotide sequence" is a nucleotide sequence that is not known to occur in nature or does not occur in nature. Generally, such a synthetic nucleotide sequence will contain at least one nucleotide difference when compared to any other naturally occurring nucleotide sequence.

[0035] As used herein, the term "nucleic acid" refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides, or their analogs. The term refers to the primary structure of the molecule, and thus includes double- and single-stranded DNA, as well as double- and single-stranded RNA. It also includes modified nucleic acids, such as methylated and / or capped nucleic acids, nucleic acids containing modified bases, backbone modifications, etc. The terms "nucleic acid" and "nucleotide sequence" are used interchangeably.

[0036] As used herein, the term "gene" refers to any segment of DNA associated with a biological function. Thus, genes include, but are not limited to, coding and / or regulatory sequences necessary for their expression. Genes may also include non-expressed DNA segments that, for example, form recognition sequences for other proteins. Genes may be obtained from a variety of sources, including cloning from a source of interest or synthesis from known or predicted sequence information, and may include sequences designed to have desired parameters.

[0037] As used herein, the terms "homologous" or "homologs" or "orthologs" are known in the art and refer to related sequences that share a common ancestor or family member and are determined based on the degree of sequence identity. The terms "homology", "homologous", "substantially similar", and "substantially corresponding" are used interchangeably herein. They refer to nucleic acid fragments in which changes in one or more nucleotide bases do not affect the ability of the nucleic acid fragment to mediate gene expression or generate a particular phenotype. These terms also refer to modifications of the nucleic acid fragments of the present disclosure, such as the deletion or insertion of one or more nucleotides, that do not substantially alter the functional properties of the resulting nucleic acid fragment as compared to the original unmodified fragment. Thus, as those skilled in the art will appreciate, it is understood that the present disclosure encompasses more than specific exemplary sequences. These terms describe the relationship of a gene found in one species, subspecies, variety, cultivar, or strain to the corresponding or equivalent gene in another species, subspecies, variety, cultivar, or strain. For purposes of this disclosure, homologous sequences are compared. "Homologous sequences" or "homologs" or "orthologs" are thought, believed, or known to be functionally related. Functional relationships may be indicated in any one of several ways, including but not limited to: (a) degree of sequence identity, and / or (b) same or similar biological function. Preferably, both (a) and (b) are indicated. Homology can be determined using software programs readily available in the art, such as those described in Current Protocols in Molecular Biology (FMA Usubel et al., eds., 1987) Supplement 30, section 7.718, Table 7.71. Some alignment programs include MacVector (Oxford Molecular Ltd, Oxford, UK), ALIGN (Amplifier), and others. Plus (Scientific and Educational Software, PA), and AlignX (Vector NTI, Invitrogen, Carlsbad, CA). Another alignment program is Sequencher (Gene Codes, Ann Arbor, MI), using default parameters.

[0038] As used herein, the term "nucleotide change" refers to, for example, a nucleotide substitution, deletion, and / or insertion, as is well understood in the art. For example, mutations contain modifications that produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded protein or the way the protein is made.

[0039] As used herein, the term "protein modification" refers to, for example, amino acid substitutions, amino acid modifications, deletions, and / or insertions, as is well understood in the art.

[0040] As used herein, the term "at least a portion" or "fragment" of a nucleic acid or polypeptide refers to a portion having a minimum size characteristic of such sequence, or any larger fragment of a full-length molecule up to the full-length molecule. A fragment of a polynucleotide of the present disclosure may encode a biologically active portion of a genetic regulatory element. A biologically active portion of a genetic regulatory element can be prepared by isolating a portion of one of the polynucleotides of the present disclosure, including the genetic regulatory element, and evaluating the activity described herein. Similarly, a portion of a polypeptide may be 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, etc. up to the full-length polypeptide. The length of the portion to be used will depend on the particular application. A portion of a nucleic acid useful as a hybridization probe may be as short as 12 nucleotides, and in some embodiments, it is 20 nucleotides. A portion of a polypeptide useful as an epitope may be as short as 4 amino acids. A portion of a polypeptide that performs the function of a full-length polypeptide will generally be longer than 4 amino acids.

[0041] Diverse polynucleotides also include sequences derived from mutagenic and recombinogenic procedures such as DNA shuffling. Strategies for such DNA shuffling are known in the art. See, for example, Stemmer (1994) PNAS 91:10747-10751; Stemmer (1994) Nature 370:389-391; Crameri et al. (1997) Nature Biotech. 15:436-438; Moore et al. (1997) J. Mol. Biol. 272:336-347; Zhang et al. (1997) PNAS 94:4504-4509; Crameri et al. (1998) Nature 391:288-291; and U.S. Patent Nos. 5,605,793 and 5,837,458. For PCR amplification of the polynucleotides disclosed herein, oligonucleotide primers can be designed for use in PCR reactions to amplify corresponding DNA sequences of cDNA or genomic DNA extracted from any organism of interest. Methods for designing PCR primers and PCR cloning are generally known in the art and are disclosed in Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2nd ed., Cold Spring Harbor Laboratory Press, Plainview, New York). Innis et al., eds. (1990) PCR Protocols: A Guide to Methods and Applications (Academic Press, New York); Innis et al., eds. (1990) PCR Protocols: A Guide to Methods and Applications (Academic Press, New York); and Gelfand, eds. (1995) PCR Strategies (Academic Press, New York); and Innis and Gelfand, eds. (1999) PCR Methods Manual (Academic Press, New York. Known methods of PCR include, but are not limited to, methods using paired primers, nested primers, single specific primers, degenerate primers, gene specific primers, vector specific primers, partially mismatched primers, and the like.

[0042] As used herein, the term "MIC" refers to maximum information coefficient. MIC is a type of non-parametric network analysis that identifies a score (MIC score) between the active microbial strains of the present disclosure and at least one measured metadata (e.g., milk fat). Additionally, U.S. Application No. 15 / 217,575, filed July 22, 2016 (issued as U.S. Patent No. 9,540,676 on January 10, 2017), is incorporated herein by reference in its entirety.

[0043] As used herein, "shelf-stable" refers to functional attributes and new usefulness provided by a microorganism formulated according to the present disclosure, which allows the microorganism to exist in a useful / active state outside of its natural environment (i.e., significantly different properties). Thus, shelf-stability is a functional attribute created with the formulation / composition of the present disclosure, indicating that the microorganism formulated in a shelf-stable composition can exist outside of its natural environment under ambient conditions for a period of time that can be determined depending on the particular formulation utilized, but generally means that the microorganism can be formulated to exist in a stable composition under ambient conditions for at least several days, generally at least one week.

[0044] Continuous saving method In some embodiments, the present disclosure provides a method for improving the viability of a microorganism after storage by subjecting the microbial culture to successive preservation challenges and preparing a product from the population of viable preservation challenge microorganisms present in the culture at the end of the preservation challenges. In some embodiments, the microbial culture is subjected to at least one preservation challenge. In some embodiments, the microbial culture is subjected to at least two, three, four, five, or more preservation challenges.

[0045] In some embodiments, the present disclosure provides a method of improving viability of a microorganism after storage, comprising: (a) subjecting a population of target microbial cells to a first storage challenge to obtain a population of challenge microbial cells; (b) harvesting viable challenge microbial cells from the population of challenge microbial cells; (c) preserving the viable challenge microbial cells to obtain a population of preserved viability-enhanced microbial cells; and (d) preparing a product using the population of preserved viability-enhanced microbial cells.

[0046] In some embodiments, the disclosure provides a method for microbial viability enhancement and preservation, the method comprising: (a) subjecting a population of target microbial cells to a first preservation challenge to obtain a first population of challenge microbial cells; (b) harvesting viable challenge microorganisms from the first population of challenge microbial cells to obtain a first population of viable challenge microbial cells; (c) subjecting the first population of viable challenge microbial cells to a second preservation challenge to obtain a second population of challenge microbial cells; (d) harvesting viable challenge microorganisms from the second population of challenge microbial cells to obtain a second population of viable challenge microbial cells; (e) preserving the second population of viable challenge microbial cells to obtain a preserved population of viable challenge microbial cells; and (f) preparing a product using the preserved population of viable challenge microbial cells.

[0047] In some embodiments, the target strain is identified (30001), as shown in the flow chart of FIG. 1. Identification of the target strain may include one or more of the disclosed methods described in U.S. Patent No. 9,938,558, the entirety of which is expressly incorporated by reference herein for all purposes. For example, in one aspect of the present disclosure, a method for identifying one or more active microorganisms from a plurality of samples is disclosed, comprising determining the absolute cell count of one or more active microbial strains in the samples, and analyzing the microorganisms with at least one metadata, wherein the one or more active microbial strains are present in the microbial community of the samples. The one or more microbial strains may be sub-taxa of a type of microorganism.

[0048] Next, once a target strain is identified (30001), an initial culture of that strain is grown (30003). Cells are then harvested from the initial culture (30006). Once harvested (30006), a pre-challenge baseline can be established and / or initial viability can be tested (30009). Once harvested, the cells are prepared for challenge (30012), for example, by combining with a storage solution.

[0049] Once the cells are prepared for challenge (30012), an initial preservation challenge is performed (30015). Examples of preservation challenges include, but are not limited to, freeze-drying (also called lyophilization), preservation by vitrification (also called preservation by glass formation), preservation by evaporation, cryopreservation, preservation by foam formation (PFF), preservation by vaporization (PBV), cryopreservation, spray drying, adsorption drying, extrusion, fluidized bed drying, and the like.

[0050] According to some embodiments, there may be multiple challenges prior to incorporation into the final product. In some embodiments, the challenge(s) may be the same as the final storage, while in other embodiments, there may be multiple types of challenges used, each of which may be the same or different from the final storage. For example, if the PBV is the final stabilization / storage step, the challenge(s) may include a PBV challenge, and in some embodiments may also include a cryopreservation challenge in addition to the PBV challenge and the final PBV process.

[0051] Once the initial preservation challenge has been performed (30015), challenge organism cells are prepared and grown in a rescue culture (30018), and cells of the rescue culture are harvested (30021) and tested for viability (30024). The challenge strain (30027) is prepared for a further preservation challenge (30030) and can be subjected to one or more further preservation challenges (30015) (which may be the same or different from the previous challenge(s) and / or final preservation, as described above).

[0052] Once the challenge is complete (30027), surviving challenge cells are harvested from the rescue culture for storage (30033), and the harvested challenge cells are retained (30036) to provide viability-enhanced cells (30036). The viability-enhanced cells can then be incorporated into a final product, such as an ensemble, a live microbial feed additive, a live microbial supplement, etc.

[0053] 2 provides a further schematic diagram of the sequential conservation challenge method described herein. Additionally, in some embodiments, genetic analysis of strains was performed to compare microbial populations that were subjected to conservation challenge and microbial populations that were not subjected to conservation challenge.

[0054] In some embodiments, the methods provided herein involving continuous storage of microbial cultures result in an increase in microbial viability of at least 5%. In other words, the viability of the microbial population present at the end of a continuous storage challenge is increased by at least 5% compared to the viability of the microbial population present prior to any storage challenge. In some embodiments, the methods provided herein involving continuous storage of microbial cultures result in an increase in microbial viability of about 5% to about 30%, about 5% to about 25%, about 5% to about 20%, about 5% to about 15%, about 5% to about 10%, about 10% to about 30%, about 15% to about 30%, about 20% to about 30%, or about 25% to about 30%. In some embodiments, the methods provided herein involving continuous storage of a microbial culture result in an increase in microbial viability of about 10% to about 30%, about 15% to about 30%, about 20% to about 30%, about 25% to about 30%, about 10% to about 25%, about 10% to about 20%, or about 10% to about 15%. In some embodiments, the methods provided herein involving continuous storage of a microbial culture result in an increase in microbial viability of at least 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, or more.

[0055] Save Challenge In some embodiments, the disclosure provides methods of improving the viability of a microorganism after storage by subjecting a microbial culture to successive preservation challenges, where the microorganism is subjected to one or more preservation challenges, in some embodiments, the microorganism is subjected to two, three, four, five, or more preservation challenges prior to final preservation for storage and / or incorporation into a product.

[0056] In some embodiments, each of the preservation challenges is of the same type. For example, in some embodiments, the microorganism is subjected to two, three, four, five, or more preservation challenges prior to final preservation for storage and / or incorporation into a product, and each of the preservation challenges is of the same type (e.g., freeze-drying / lyophilization, respectively, preservation by vitrification / glass formation, respectively, preservation by evaporation, respectively, preservation by foam formation, respectively, preservation by vaporization, respectively, cryopreservation, respectively, spray drying, respectively, adsorption drying, respectively, extrusion, or respectively, fluidized bed drying).

[0057] In some embodiments, the preservation challenges are different types of preservation challenges. For example, in some embodiments, the microorganism is subjected to a first and a second preservation challenge, and the first and the second preservation challenge are different challenge types. For example, in some embodiments, the first preservation challenge is a cryogenic preservation challenge, and the second preservation challenge is a freeze-dried preservation challenge. Exemplary combinations of preservation challenge types are shown in Table 1 below. [Table 1-1] [Table 1-2] [Table 1-3]

[0058] Freeze-drying (FD) / Lyophilization In some embodiments, the population of target microbial cells is subjected to freeze-drying preservation (also called lyophilization preservation). Freeze-drying, or lyophilization, is known and applied to preserve various types of proteins, cells, viruses, and microorganisms. FD usually includes primary and secondary drying. Freeze-drying can be used to produce stable bioactive substances in industrial quantities. Freeze-drying can damage cellular components and can result in reduced viability, and traditionally, freeze-dried products are usually only stable at or near 0°C, which can require the bioactive substance product to be cooled from the time it is produced to the time it is utilized, and requires cooling during storage and transportation.

[0059] A. Primary freeze-drying The limitations of freeze-drying as described above are due in part to the need to utilize low pressure (or high vacuum) during the freeze-drying process. High vacuum is required because the temperature of the material during primary freeze-drying must be below the collapse temperature, which is approximately equal to Tg'. At such low temperatures, primary drying takes many hours (possibly days) since the equilibrium pressure on ice at temperatures below -25°C is less than 0.476 Torr. Thus, new processes must make it possible to reduce production times.

[0060] The reduced pressure used in freeze-drying limits the amount of water that can be removed from drying. Primary freeze-drying is performed by sublimating ice from a frozen specimen at a temperature close to or below the Tg', which is the temperature at which the solution that remains unfrozen between the ice crystals becomes solid (vitrifies) during cooling. According to conventional thinking, performing freeze-drying at such low temperatures is important for at least two reasons. The first reason that freeze-drying at low temperatures (i.e., below the Tg') is important is that it is important to ensure that the cake remaining after removal of the ice by sublimation (primary drying) is "solid" and mechanically stable, i.e., does not collapse. Keeping the cake in a mechanically stable "solid" state after primary freeze-drying is important to ensure effective reconstitution of the freeze-dried material. Several methods have been proposed to measure the Tg' of a particular material. These methods rely on different interpretations of features that can be seen on a DSC (differential scanning calorimeter) thermogram. The most reliable method for determining Tg' is based on an assessment of the temperature at which ice begins to melt and the concentration of water (Wg') that remains unfrozen during slow cooling. The second reason commonly advanced in support of the importance of freeze-drying at low temperatures (i.e., below Tg') is that survival of bioactive materials after freeze-drying is greater if the primary freeze-drying is performed at low temperatures.

[0061] FD can be damaging to sensitive bioactive materials. Strong damage caused by FD occurs both during freezing (formation of ice crystals) and during the equilibration of frozen specimens at intermediate low temperatures during the subsequent sublimation of ice. Well-known factors that cause cell damage during freeze-drying include dehydration caused by freezing, mechanical damage of cells during ice crystallization and recrystallization, phase transformations in cell membranes, increase in electrolyte concentration, etc. Furthermore, damage to frozen bioactive materials can be caused by large pH changes in the liquid phase that remains unfrozen between the ice crystals. This abnormal pH change is associated with crystallization hydrolysis.

[0062] Crystallization hydrolysis occurs because ice crystals trap cations and anions separately. This creates a large (about 107 V / m) electric field within the ice crystals. Neutralization of this electric field occurs by electrolysis within the ice crystals at a rate proportional to the dissociation constant of the water molecules in the ice. This neutralization leads to a change in the pH of the liquid remaining between the ice crystals. The adverse effects of crystallization hydrolysis can be reduced by reducing the ice surface produced upon freezing and by increasing the volume of the liquid phase remaining between the ice crystals. Residual liquid also reduces the adverse effects of (i) an increase in electrolyte (or any other highly reactive molecule) concentration and (ii) mechanical damage to cells between the ice crystals. Increasing the liquid between the ice crystals can be achieved by (i) increasing the initial concentration of a protective agent added before freezing and (ii) decreasing the amount of ice formed in the sample.

[0063] Avoiding freezing to temperatures equal to or below Tg' (where freeze-drying is usually performed) would make it possible to significantly reduce the amount of damage to the preserved biological material. Therefore, new methods that allow the preservation of biologically active materials without subjecting them to temperatures close to or below Tg' would greatly improve the quality of the preserved material.

[0064] B. Secondary freeze-drying After the removal of ice by sublimation (primary drying) is complete, the sample can be described as a porous cake. The water concentration in the sample at the end of the primary drying exceeds the water concentration that remains unfrozen in the glass channels between the ice crystals at temperatures below Tg' (Wg'). Tg' depends strongly on the composition of the solution, but for the majority of solutes, Wg' is about 20 wt%. At such high water concentrations, the glass transition temperature of the cake material is below the primary freeze-drying temperature and / or significantly below -20°C. Secondary drying is performed to remove the remaining (about 20 wt%) water and to increase the glass transition temperature of the cake material. In practice, secondary drying cannot be performed at Tg' or lower, since the diffusion of water from a material in the glassy state is very slow. For this reason, secondary drying is performed by heating the cake to a drying temperature Td that is higher than the glass transition temperature Tg of the cake material at a given moment. If, during the secondary drying step, Td is significantly higher than Tg, the cake will "collapse" to form a very viscous syrup, which will make standard reconstitution impossible. Therefore, cake collapse is highly undesirable.

[0065] The collapse phenomenon, which is dynamic in nature, has been widely discussed in the literature. As the viscosity of the cake material decreases, the rate of collapse increases. To avoid the collapse process or to make it negligible, Td is kept close to Tg during secondary drying, thereby increasing the viscosity of the cake material and slowing down the rate of collapse.

[0066] Preservation by vitrification (glass formation) In some embodiments, a population of target microbial cells is subjected to preservation by vitrification. "Preservation by vitrification" is the transformation from a liquid to a significantly immobile, non-crystalline, amorphous solid state known as the "glassy state". Such a process may also be referred to as "preservation by glass formation". The "glassy state" is an amorphous solid state, which may be achieved by supercooling a substance that was initially in a liquid state. Diffusion (e.g., "glass") in vitrified substances occurs at a very low rate. Thus, chemical and biological changes that require the interaction of multiple parts are virtually completely suppressed. Glass usually appears as a homogeneous, transparent, brittle solid that can be crushed or milled. Above a temperature known as the glass transition temperature (Tg), the viscosity drops sharply and the substance transforms from the glassy state to what is known as the deformable "rubbery state". As the temperature increases, the substance transitions to a liquid state. The optimal benefits of vitrification for long-term storage may only be ensured under conditions where the Tg is higher than the storage temperature.

[0067] Vitrification is widely used to preserve biological and highly reactive chemicals. The basic premise of vitrification is that all diffusion-restricted physical processes and chemical reactions, including those involved in the decomposition of biological materials, cease in the glassy state. In general terms, glass is a thermodynamically unstable amorphous substance that is mechanically stable at very high viscosities (1012-1014 Pa / s). For typical liquids, the flow rate is 10 -14 m / s, compared with a flow velocity of 10 m / s.

[0068] Bioactive substances can be stored at -196°C. The Tg of pure water is approximately -145°C. If ice crystals form during cooling, the solution that remains unfrozen in the channels between the ice crystals will vitrify at a Tg' higher than the Tg of pure water. Bioactive substances that are rejected in the channels during ice growth will be stable at temperatures below Tg'. Bioactive substances can be stabilized at temperatures significantly higher than -145°C if placed in concentrated storage solutions with high Tg. For example, for a solution containing 80% sucrose, the Tg is approximately -40°C. A solution containing 99% sucrose is characterized by a Tg of approximately 52°C. The presence of moisture in the sample leads to a strong plasticizing effect, which reduces the Tg. The Tg depends directly on the amount of water present and can therefore be modified by controlling the level of hydration - the less water, the higher the Tg. Therefore, specimens (which will be vitrified at ambient temperature) must be strongly dehydrated by drying. However, drying can be damaging to bioactive materials, and therefore, to stabilize bioactive materials at room temperature and still preserve their viability and function, they must be dried in the presence of a protective excipient (i.e., a protective agent) or combination of excipients, which have a glass transition temperature Tg above room temperature.

[0069] Preservation by evaporation In some embodiments, the population of target microbial cells is subjected to evaporative preservation, which refers to a process that involves the removal of water by evaporative drying.

[0070] In some embodiments, the activity of the biologically active material dried by evaporative drying of the droplets is comparable to that of the lyophilized sample. For example, it has been shown that labile enzymes (luciferase and isocitrate dehydrogenase) can be preserved by evaporative drying at 50° C. for over a year without detectable loss of activity during drying and subsequent storage at 50° C. It can take a long time to evaporate water even from a droplet of solution, as the dehydrated solution containing the protectant becomes viscous.

[0071] Preservation by foam formation In some embodiments, the population of target microbial cells is subjected to preservation by foam formation. During preservation by foam formation (PFF), the biological material is first transformed into a mechanically stable dry foam by boiling under vacuum at ambient temperature above the freezing point (called primary drying). The sample is then subjected to high temperature stable drying to increase the glass transition temperature. The resulting viability or activity after rehydration of the preserved sample is achieved by the appropriate selection of preservatives (e.g., sugars) dissolved in the suspension before PFF and by the appropriate selection of vacuum and temperature protocols during PFF (see Bronshtein, Victor. (2004). Bronshtein 2004 Preservation by Foam Formulation. PharmTech. Pharmaceutical Technology. 28. 86-92).

[0072] Preservation by evaporation In some embodiments, the population of target microbial cells is subjected to preservation by vaporization. Preservation by vaporization (PBV) is a preservation process that includes primary drying and stable drying. Primary drying is performed by intensive vaporization (sublimation, boiling, and evaporation) of water from a partially frozen and simultaneously heated material at temperatures significantly above Tg' (about 10°C or higher) (i.e., the vacuum pressure is below the equilibrium pressure of water vapor).

[0073] In the PBV, boiling during primary drying does not produce much splashing because the equilibrium pressure at the freezing temperatures above the slush is low and ice crystals on the surface of the slush prevent or inhibit splashing. Typically, a material being subjected to PBV drying (e.g., a frozen solution or suspension) appears as a foam partially covered by a thin skim of freeze-dried cake.

[0074] Unlike preservation by foam formation (PFF), preservation by vaporization (PBV) can be very effective in preserving bioactive substances contained or incorporated in alginate gel formulations and other gel formulations. The PBV process can be carried out by drying frozen gel particles under vacuum at slightly negative temperatures (on the Celsius scale). In such hydrogel systems, vaporization involves the sublimation of ice crystals, boiling of water within unfrozen microinclusions, and evaporation from the gel surface.

[0075] During the first drying of freeze-drying g PBVs can differ from freeze-drying because freeze-drying implies a product processing temperature below 25°C (usually below -25°C) and because freeze-drying implies avoiding the "collapse" phenomenon during both primary and secondary drying. PBVs are based on the T g 'Drying at temperatures significantly higher than -15°C, preferably higher than -10°C, more preferably higher than -5°C.

[0076] Additional details regarding PBV and other challenges can be found in U.S. Patent Application Publication No. 2008 / 0229609, the entirety of which is hereby expressly incorporated by reference herein for all purposes.

[0077] cold storage In some embodiments, the population of target microbial cells is subjected to cryopreservation. Cryopreservation refers to the use of very low temperatures to preserve structurally intact living cells and tissues. The adverse effects of cryopreservation are mainly associated with freezing-induced dehydration, changes in pH, increases in extracellular concentrations of electrolytes, phase transformations of biological membranes and macromolecules at low temperatures, and other processes associated with ice crystallization. Potential cryodamage is a drawback of methods that rely on freezing of biologically active substances. This damage can be reduced by using cryoprotective excipients (protectants), such as glycerol, ethylene glycol, dimethyl sulfoxide (DMSO), sucrose and other sugars, amino acids, synthetic, and / or biological polymers.

[0078] spray drying In some embodiments, the population of target microbial cells is subjected to preservation by spray drying. Spray drying refers to a method of producing a dry powder from a liquid or slurry by rapid drying with hot gas. Spray drying generally involves spraying a suspension of microorganisms into a stream of hot air in a chamber, the chamber containing an inlet for the heated air, an outlet for exhausting the air, and an outlet for collecting the dried microbial powder. Exemplary temperatures, chamber volumes, and gases used in spray drying processes can be found in U.S. Patent No. 6,010,725.

[0079] Adsorption drying In some embodiments, the population of target microbial cells is subjected to preservation by adsorptive drying, which refers to a method that involves the removal of water by diffusion and adsorption onto porous materials such as alumina, silica gel, molecular sieves, and other chemical desiccants.

[0080] Extrusion In some embodiments, the population of target microbial cells is subjected to preservation by extrusion. Extrusion refers to a method in which a material is forced through a die to form a material. In some embodiments, the target microbial cells are dispersed in a carrier or matrix to protect them from oxygen, heat, moisture, etc.

[0081] Fluidized bed drying In some embodiments, the population of target microbial cells is subjected to preservation by fluidized bed drying. Fluidized bed drying refers to a method in which particles are fluidized in a bed and dried. A fluidized bed is formed when a quantity of solid particulates is subjected to conditions that cause the solid material to behave like a fluid. In a fluidized bed drying system, the incoming air provides a significant airflow to support the weight of the particles.

[0082] Stable drying In some embodiments, the population of target microbial cells is subjected to a drying method (e.g., freeze-drying, vitrification / glass-forming preservation, evaporative preservation, foam preservation, vapor preservation, spray drying, adsorption drying, or fluid bed drying), and the dry preservation method further comprises stable drying, which is performed to (1) further increase the glass transition temperature of the dried material, (2) mechanically stabilize the dried material at ambient temperature without vacuum, and (3) preserve the potency and efficacy of the biological agent during long-term storage at ambient temperature.

[0083] For example, the T of a substance g to 37°C, thereby allowing it to stabilize at this temperature, and the stabilization drying step should be carried out at a temperature significantly higher than 37°C for several hours in order to remove water from the interior of the already dried material.

[0084] The process of dehydration of biological specimens at high temperatures can be very damaging to the subject bioactive substances if the temperature used for drying is higher than the applicable protein denaturation temperature. To protect the sample from damage that can be caused by high temperatures, a stable dehydration process (i.e., stable drying) may need to be carried out gradually. The first step (either in air or in vacuum) should be carried out at a starting temperature to ensure dehydration without significantly compromising the viability and efficacy of the organism. After such a first drying step, the process of dehydration can be continued in subsequent steps by drying at gradually higher temperatures in each subsequent step. Each step allows for a concomitant increase in the degree of dehydration achievable and the temperature used for drying in the following steps.

[0085] Storage solution In some embodiments, the microbial population to be subjected to one or more preservation challenges is first suspended in a preservation solution. Exemplary preservation solutions may include, by way of non-limiting example, intracellular protectants (e.g., sugars, particularly non-reducing sugars; sugar alcohols, such as sorbitol), pH buffers (e.g., monosodium glutamate, monopotassium phosphate, dipotassium phosphate, etc.), membrane protectants (e.g., polyvinylpyrrolidone K-15, etc.), as well as components that aid in preservation (e.g., sucrose, where applicable, for glass formation, etc.) and quality control (e.g., redox indicators, such as resazurin, for use with anaerobic microorganisms, etc.).

[0086] In some embodiments, the intracellular protectant is selected from sorbitol, mannitol, glycerol, maltitol, xylitol, erythritol, and methyl glucoside. In some embodiments, the membrane protectant is selected from sucrose, trehalose, raffinose, polyvinylpyrrolidone, maltodextrin, and polyethylene glycol. In some embodiments, the storage solution includes one or more buffers, such as phosphate.

[0087] In some embodiments, the preservation solution is tailored to the type of preservation challenge used in the sequential preservation method. Those skilled in the art will be familiar with the components of the preservation solution (e.g., intracellular protectants, pH buffers, membrane protectants, etc.) and the combinations applicable to each preservation method. For example, a preservation solution used for preservation by foam formation or preservation by evaporation may require a higher concentration of sugar compared to a preservation solution used for other types of preservation challenges.

[0088] Exemplary preservation solutions are provided in Tables 3A-3C in the Examples below. Additional preservation solutions are described in the art, for example, in US Patent No. 6,872,357.

[0089] microbial source In some embodiments, the present disclosure provides a method for improving the viability of microorganisms after storage by subjecting a microbial culture to successive storage challenges and preparing a product from the population of viable storage challenge microorganisms present in the culture at the end of the storage challenges. The target microbial population may be any microorganism suitable for storage by the methods described herein. As used herein, the term "microorganism" should be interpreted broadly. It includes, but is not limited to, the two prokaryotic domains bacteria and archaea, and the eukaryotic domains fungi, protists, and viruses. By way of example, the microorganism may include species of the genera Clostridium, Ruminococcus, Roseburia, Hydrogenoanaerobacterium, Saccharofermentans, Papillibacter, Pelotomaculum, Butyricicoccus, Tannerella, Prevotella, Butyricimonas, Piromyces, Pichia, Candida, Vrystaatia, Orpinomyces, Neocallimastix, and Phyllosticta. The microorganism may further include species belonging to the family Lachnospiraceae and the order Saccharomycetales, hi some embodiments, the microorganism may include species of any genera disclosed herein.

[0090] In one embodiment, the microorganisms are obtained from animals (e.g., mammals, reptiles, birds, etc.), soil (e.g., rhizosphere), air, water (e.g., seawater, freshwater, wastewater sludge), sediment, oil, plants (e.g., roots, leaves, stems), agricultural products, and extreme environments (e.g., acid mine drainage or hydrothermal systems). In further embodiments, the microorganisms are obtained from marine or freshwater environments such as oceans, rivers, or lakes. In further embodiments, the microorganisms can be from the surface of a body of water, or from a body of water at any depth (e.g., deep sea samples).

[0091] The microorganisms of the present disclosure may be isolated in substantially pure cultures or mixed cultures. They may be concentrated, diluted, or provided in the natural concentrations found in the source material. For example, microorganisms from saline sediments may be isolated for use in the present disclosure by suspending the sediment in fresh water and allowing the sediment to settle to the bottom. The water containing the majority of the microorganisms may be removed by settling after a suitable period of settling and administered to the gastrointestinal tract of an ungulate, or may be concentrated by filtration or centrifugation, diluted to an appropriate concentration, and administered to the gastrointestinal tract of an ungulate where most of the salt is removed. As another example, in the case of application to ungulates to minimize the possibility of injury to the animal, microorganisms from calcified or toxic sources may be similarly treated to recover the microorganisms.

[0092] In another embodiment, the microorganism is used in a crude form that is not isolated from the naturally occurring source material.For example, the microorganism is provided in combination with the source material that is present, for example, in fecal matter, regurgitation, or other compositions found in the gastrointestinal tract.In this embodiment, the source material may contain one or more species of microorganisms.

[0093] In some embodiments, a mixed population of microorganisms is used in the methods of the present disclosure. In embodiments of the present disclosure in which microorganisms are isolated from source materials (e.g., materials in which they occur naturally), any one or combination of a number of standard techniques that will be readily known to those skilled in the art may be used. However, by way of example, they generally use processes that can obtain solid or liquid cultures of single microorganisms in substantially pure form, usually by physical separation on the surface of a solid microbial growth medium, or by volumetric dilutive isolation into a liquid microbial growth medium. These processes may include isolation from dry materials, liquid suspensions, slurries, or homogenates, where the material is spread in a thin layer on a suitable solid gel growth medium, or serial dilution of the material into a sterile medium and inoculation into a liquid or solid culture medium.

[0094] In some embodiments, the material containing the microorganisms may be pretreated prior to the isolation process to enrich for all microorganisms within the material. The microorganisms can then be isolated from the enriched material.

[0095] The target microorganisms subjected to the preservation method described herein can be derived from any sample type that contains a microbial community. For example, the samples used in the methods provided herein include, but are not limited to, animal samples (e.g., mammals, reptiles, birds), soil, air, water (e.g., seawater, freshwater, wastewater sludge), sediment, oil, plants, agricultural products, plants, soil (e.g., rhizosphere) and extreme environmental samples (e.g., acid mine drainage, hydrothermal systems). In the case of seawater or freshwater samples, the sample can be from the surface of a body of water or any depth of a body of water, for example, a deep sea sample. In one embodiment, the water sample is an ocean, river, or lake sample.

[0096] In one embodiment, the animal sample is a bodily fluid. In another embodiment, the animal sample is a tissue sample. Non-limiting animal samples include teeth, sweat, fingernails, skin, hair, feces, urine, semen, mucus, saliva, and gastrointestinal tract. The animal sample can be, for example, a human, primate, bovine, porcine, canine, feline, rodent (e.g., mouse or rat), equine, or avian sample. In one embodiment, an avian sample includes a sample from one or more chickens. In another embodiment, the sample is a human sample. The human microbiota includes a collection of microorganisms found in the surface and deep layers of the skin, mammary gland, saliva, oral mucosa, conjunctiva, and gastrointestinal tract. Microorganisms found in the microbiota include bacteria, fungi, protozoa, viruses, and archaea. Different parts of the body exhibit different diversity of microorganisms. The amount and type of microorganisms can inform the health or disease state of an individual. The number of bacterial taxa can be in the thousands, and viruses can be abundant. The bacterial composition at a given site in the body varies from individual to individual not only in type but also in abundance or quantity.

[0097] In another embodiment, the sample is a ruminal sample. Ruminant animals, such as cattle, rely on a diverse microbial community to digest their feed. These animals have evolved to use feed with low nutritional value by having a modified upper digestive tract (the reticulum or rumen) where the feed is retained while being fermented by a community of anaerobic microorganisms. The ruminal microbial community is approximately 3×10 per milliliter. 10 The rumen is highly dense with microbial cells of various ages. Anaerobic fermenting microorganisms predominate in the rumen. The microbial community in the rumen includes members of all three domains of organisms: Bacteria, Archaea, and Eukarya. Fermentation products within the rumen are required by the respective host for body maintenance and growth as well as milk production (van Houtert (1993). Anim. Feed Sci. Technol. 43, pp. 189-225; Bauman et al. (2011). Annu. Rev. Nutr. 31, pp. 299-319; each of which is incorporated by reference in its entirety for all purposes). Additionally, milk yield and composition have been reported to be associated with the microbial community within the rumen (Sandri et al. (2014). Animal 8, pp. 572-579; Palmonari et al. (2010). J. Dairy Sci. 93, pp. 279-287; each of which is incorporated by reference in its entirety for all purposes). In one embodiment, ruminal samples are collected via the process described in Jewell et al. (2015). Appl. Environ. Microbiol. 81, pp. 4697-4710, which is incorporated by reference in its entirety for all purposes.

[0098] In another embodiment, the sample is a soil sample (e.g., bulk soil or rhizosphere sample). It has been estimated that one gram of soil contains tens of thousands of bacterial taxa and up to one billion bacterial cells, as well as approximately 200 million fungal hyphae (Wagg et al. (2010). Proc Natl. Acad. Sci. USA 111, pp. 5266-5270, incorporated by reference in its entirety for all purposes). Bacteria, actinomycetes, fungi, algae, protozoa, and viruses are all found in soil. The diversity of soil microbial communities is involved in the organization and fertility of the soil microenvironment, plant nutrient acquisition, plant diversity and growth, and nutrient acquisition through resource cycling between above- and below-ground communities. Thus, assessing the microbial content and co-occurrence of active microorganisms (as well as the number of active microorganisms) of soil samples over time provides insight into the microorganisms associated with environmental metadata parameters, such as nutrient acquisition and / or plant diversity.

[0099] In one embodiment, the soil sample is a rhizosphere sample, i.e., a small area of ​​soil directly affected by root exudates and associated soil microorganisms. The rhizosphere is a dense area where elevated microbial activity has been observed and where plant roots interact with soil microorganisms through the exchange of nutrients and growth factors (San Miguel, 2001, incorporated by reference in its entirety for all purposes). (Eds. et al. (2014). Appl. Microbiol. Biotechnol. DOI 10.1007 / s00253-014-5545-6). Because plants secrete many compounds into the rhizosphere, analysis of the types of organisms in the rhizosphere can be useful to determine the characteristics of the plants growing therein.

[0100] In another embodiment, the sample is a seawater or freshwater sample. The ocean contains up to one million microorganisms and thousands of microbial types per milliliter. These figures can be orders of magnitude or more in coastal waters with their high productivity and high organic matter and nutrient loading. Marine microorganisms are crucial for the functioning of marine ecosystems: maintaining the balance between produced and fixed carbon dioxide; producing more than 50% of the oxygen on earth by marine photosynthetic microorganisms, such as Cyanobacteria, diatoms, and pico- and nano-phytoplankton; providing novel bioactive compounds and metabolic pathways; and ensuring a sustainable supply of seafood by occupying an important lowest trophic level of the marine food web. Organisms found in marine environments include viruses, bacteria, archaea, and some eukaryotes. Marine viruses may play an important role in controlling the population of marine bacteria through virus lysis. Marine bacteria are important not only as producers of organic matter but also as a food source for other small microorganisms. Archaea found throughout the ocean water column are pelagic archaea, and their abundance is comparable to that of marine bacteria.

[0101] In another embodiment, the sample includes a sample from an extreme environment, i.e., an environment with conditions that are harmful to most organisms on Earth. Organisms that grow in extreme environments are called extremophiles. While the domain Archaea contains well-known examples of extremophiles, the domain Bacteria may also have representatives of these organisms. Extremophiles include: acidophiles that grow at pH levels below 3; alkaliphiles that grow at pH levels above 9; anaerobes such as Spinoloricus Cinzia that do not require oxygen to grow; cryptoendoliths that live in microscopic spaces, fissures, aquifers, and faults in rocks filled with groundwater deep underground; halophiles that grow at salt concentrations of at least about 0.2M; hyperthermophiles that grow at high temperatures (about 80-122°C) found in hydrothermal systems; hypoliths that live under rocks in cold deserts; Nitrosomonas that derive energy from reduced mineral compounds such as pyrite and are active in geochemical cycles. europaea; metal-tolerant organisms that tolerate high levels of dissolved heavy metals such as copper, cadmium, arsenic, and zinc; oligotrophs that grow in nutritionally limited environments; hypertrophs that grow in environments with high sugar concentrations; piezophiles (or barophiles) that grow at high pressures such as those found in the ocean or deep underground; psychrophiles / cryophiles that live, grow, and / or reproduce at temperatures below about -15°C; radiotolerant organisms that can tolerate high levels of ionizing radiation; thermophiles that grow at temperatures between 45 and 122°C; xerophiles that can grow in very dry conditions. Polyextremophiles are organisms that qualify as extremophiles under multiple categories and include thermoacidophilic archaea (which prefer temperatures between 70 and 80°C and a pH between 2 and 3). The crenarchaeal group of archaea includes thermoacidophilic archaea.

[0102] A sample may include microorganisms from one or more domains. For example, in one embodiment, a sample includes a heterogeneous population of bacteria and / or fungi (also referred to herein as bacterial or fungal strains). For example, one or more microorganisms may be from the domains Bacteria, Archaea, Eukarya, or combinations thereof. Bacteria and Archaea are prokaryotes with a very simple cell structure without internal organelles. Bacteria can be classified into phyla Gram-positive / outer membraneless, Gram-negative / outer membrane, and ungrouped. Archaea constitute a domain or kingdom of unicellular microorganisms. Archaea are visually similar to bacteria, but have genes and some metabolic pathways more closely related to eukaryotic metabolic pathways, particularly enzymes involved in transcription and translation. Other aspects of archaeal biochemistry are unique, such as the presence of ether lipids in the cell membrane. Archaea are divided into four recognized phyla: Thaumarchaeota, Aigarchaeota, Crenarchaeota, and Korarchaeota.

[0103] The domain Eukarya includes eukaryotes, which are defined by membrane-bound organelles such as a nucleus. Protozoa are single-celled eukaryotes. All multicellular organisms are eukaryotes, including animals, plants, and fungi. Eukaryotes are classified into four kingdoms: Protists, Plantae, Fungi, and Animalia. However, several alternative classifications exist. Another classification divides eukaryotes into six kingdoms: Excavata (various flagellated protozoa); Amoebozoa (thallus amoebas and slime fungi); Opisthokonta (animals, fungi, choanoflagellates); Rhizaria (Foraminifera, Radiolaria, and various other amoeboid protozoans); Chromalveolata (Stramenopiles (brown algae, diatoms), Haptophyta, Cryptophyta (or cryptophytes), and Alveolata); Archaeplastida / Primoplantae (land plants, green algae, red algae, and grey algae).

[0104] Within the domain of eukaryotes, fungi are the predominant microorganisms in microbial communities. Fungi include microorganisms such as yeasts and filamentous fungi, as well as the mushroom family. Fungal cells have cell walls containing glucan and chitin, which are unique characteristics of these organisms. Fungi form a single group of related organisms named Eumycota that share a common ancestor. The kingdom fungi is estimated to contain between 1.5 and 5 million species, and about 5% of these have been formally classified. Most fungal cells grow as elongated, tubular, and filamentous structures called hyphae that may contain multiple nuclei. Some species grow as unicellular yeasts that reproduce by budding or binary fission. The major phyla of fungi (sometimes called fission) are classified primarily based on the characteristics of their sexual reproductive structures. Currently, seven phyla are proposed: Microsporidia, Chytridiomycota, Blastocladiomycota, Neocallimastigomycota, Glomeromycota, Ascomycota, and Basidiomycota.

[0105] Microorganisms for detection and quantification with the methods described herein can also be viruses. Viruses are small infectious agents that replicate only within the living cells of other organisms. Viruses can infect all types of organisms within the domains of Eukarya, Bacteria, and Archaea. Virus particles (known as virions) consist of two or three parts: (i) genetic material, which can be either DNA or RNA; (ii) a protein coat that protects these genes; and in some cases, (iii) a lipid envelope that surrounds the protein coat when they are extracellular. Seven orders are provided for viruses: Caudovirales, Herpesvirales, Ligamenvirales, Mononegavirales, Nidovirales, Picornavirales, and Tymovirales. Viral genomes can be single-stranded (ss) or double-stranded (ds), RNA or DNA, and may or may not use reverse transcriptase (RT). In addition, ssRNA viruses can be either sense (+) or antisense (-). This classification separates viruses into seven groups: I: dsDNA viruses (e.g., adenoviruses, herpesviruses, poxviruses); II: (+)ssDNA viruses (e.g., parvoviruses); III: dsRNA viruses (e.g., reoviruses); IV: (+)ssRNA viruses (e.g., picornaviruses, togaviruses); V: (-)ssRNA viruses (e.g., orthomyxoviruses, rhabdoviruses); VI: (+)ssRNA-RT viruses with a DNA intermediate in their life cycle (e.g., retroviruses); VII: dsDNA-RT viruses (e.g., hepadnaviruses).

[0106] Microorganisms for detection and quantification in the methods described herein can also be viroids. Viroids are the smallest infectious pathogens known, consisting only of short chains of circular single-stranded RNA without a protein coat. They are primarily plant pathogens, some of which are economically important. Viroid genomes are very small in size, ranging from about 246 to about 467 nucleobases.

[0107] Isolated microorganisms As used herein, "isolate", "isolated", "isolated microorganism" and similar terms are intended to mean that one or more microorganisms are separated from at least one of the substances with which they are associated in a particular environment (e.g., soil, water, animal tissue). Thus, an "isolated microorganism" is not present in its naturally occurring environment, but rather, the microorganism has been removed from its natural setting by various techniques described herein and placed in a non-naturally occurring state of existence. Thus, an isolated strain may exist, for example, as a biologically pure culture or as a spore (or other form of the strain) associated with an acceptable carrier.

[0108] In certain embodiments of the present disclosure, the isolated microorganism exists as an isolated, biologically pure culture. Those skilled in the art will understand that an isolated, biologically pure culture of a particular microorganism indicates that the culture is substantially free (within scientific reason) of other living organisms and contains only the individual microorganism in question. The culture may contain various concentrations of the microorganism. The present disclosure notes that an isolated, biologically pure microorganism is necessarily distinct from a less pure or impure substance in many cases. See, e.g., In re Bergstrom, 427 F.2d 1394, (CCPA 1970) (discussing purified prostaglandins); In re Bergy, 596 F.2d See also 952 (CCPA 1979) (discussing purified microorganisms); Parke-Davis & Co. v HK Mulford & Co., 189 F. 95 (SDNY 1911) (Learned Hand on purified adrenaline), aff'd in part, rev'd in part, 196 F. 496 (2d Cir. 1912), each of which is incorporated herein by reference. Furthermore, in some aspects, the present disclosure provides certain quantitative measures of concentration or purity limits that must be found in an isolated biologically pure microbial culture. The presence of these purity values ​​is, in certain embodiments, an additional attribute that distinguishes the microorganisms of the present disclosure from those that exist in the natural state. See, for example, Merck & Co. v. Olin Mathieson Chemical Corp., 253 F.2d 156 (4th Cir. 1958) (discussing purity limits for vitamin B12 produced by microorganisms), which is incorporated herein by reference.

[0109] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species belonging to the taxonomic families of Clostridiaceae, Ruminococcaceae, Lachnospiraceae, Acidaminococcaceae, Peptococcaceae, Porphyromonadaceae, Prevotellaceae, Neocallimastigaceae, Saccharomycetaceae, Phaeosphaeriaceae, Erysipelotrichia, Anaerolineaceae, Atopobiaceae, Botryosphaeriaceae, Eubacteriaceae, Acholeplasmataceae, Succinivibrionaceae, Lactobacillaceae, Selenomonadaceae, Burkholderiaceae, and Streptococcaceae.

[0110] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product is selected from the group consisting of Acetanaerobacterium, Acetivibrio, Acidaminobacter, Alkaliphilus, Anaerobacter, Anaerostipes, Anaerotruncus, Anoxynatronum, Bryantella, Butyricicoccus, Caldanaerocella, Caloramator, Caloranaerobacter, Caminicella, Candidatus The present invention includes isolated microbial species selected from genera of the family Clostridiaceae, including Arthromitus, Clostridium, Coprobacillus, Dorea, Ethanologenbacterium, Faecalibacterium, Garciella, Guggenheimella, Hespellia, Linmingia, Natronincola, Oxobacter, Parasporobacterium, Sarcina, Soehngenia, Sporobacter, Subdoligranulum, Tepidibacter, Tepidimicrobium, Thermobrachium, Thermohalobacter, and Tindallia.

[0111] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Ruminococcaceae, including Ruminococcus, Acetivibrio, Sporobacter, Anaerofilium, Papillibacter, Oscillospira, Gemmiger, Faecalibacterium, Fastidiosipila, Anaerotruncus, Ethanoligenens, Acetanaerobacterium, Subdoligranulum, Hydrogenoanaerobacterium, and Candidadus Soleaferrea.

[0112] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Lachnospiraceae, including Butyrivibrio, Roseburia, Lachnospira, Acetitomaculum, Coprococcus, Johnsonella, Catonella, Pseudobutyrivibrio, Syntrophococcus, Sporobacterium, Parasporobacterium, Lachnobacterium, Shuttleworthia, Dorea, Anaerostipes, Hespellia, Marvinbryantia, Oribacterium, Moriella, Blautia, Robinsoniella, Cellulosilyticum, Lachnoanaerobaculum, Stomatobaculum, Fusicatenibacter, Acetatifactor, and Eisenbergiella.

[0113] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Acidaminococcaceae, including Acidaminococcus, Phascolarctobacterium, Succiniclasticum, and Succinispira.

[0114] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Peptococcaceae, including Desulfotomaculum, Peptococcus, Desulfitobacterium, Syntrophobotulus, Dehalobacter, Sporotomaculum, Desulfosporosinus, Desulfonispora, Pelotomaculum, Thermocola, Cryptanaerobacter, Desulfitibacter, Candidatus Desulforudis, Desulfurispora, and Desulfitospora.

[0115] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Porphyromonadaceae, including Porphyromonas, Dysgonomonas, Tannerella, Odoribacter, Proteiniphilum, Petrimonas, Paludibacter, Parabacteroides, Barnesiella, Candidatus Vestibaculum, Butyricimonas, Macellibacteroides, and Coprobacter.

[0116] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus in the family Anaerolineaceae, including Anaerolinea, Bellilinea, Leptolinea, Levilinea, Longilinea, Ornatilinea, and Pelolinea.

[0117] In some embodiments, the disclosure provides a microbial product prepared by a method described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Atopobiaceae, including Atopbium and Olsenella.

[0118] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Eubacteriaceae, including Acetobacterium, Alkalibacter, Alkalibaculum, Aminicella, Anaerofustis, Eubacterium, Garciella, and Pseudoramibacter.

[0119] In some embodiments, the disclosure provides a microbial product prepared by a method described herein, wherein the microbial product comprises an isolated microbial species selected from a genus in the family Acholeplasmataceae, including Acholeplasma.

[0120] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Succinivibrionaceae, including Anaerobiospirillum, Ruminobacter, Succinatimonas, Succinimonas, and Succinivibrio.

[0121] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Lactobacillaceae, including Lactobacillus, Paralactobacillus, Pediococcus, and Sharpea.

[0122] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Selenomonadaceae, including Anaerovibrio, Centipeda, Megamonas, Mitsuokella, Pectinatus, Propionispira, Schwartzia, Selenomonas, and Zymophilus.

[0123] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Burkholderiaceae, including Burkholderia, Chitinimonas, Cupriavidus, Lautropia, Limnobacter, Pandoraea, Paraburkholderia, Paucimonas, Polynucleobacter, Ralstonia, Thermothrix, and Wautersia.

[0124] In some embodiments, the disclosure provides a microbial product prepared by a method described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Streptococcaceae, including Lactococcus, Lactovum, and Streptococcus.

[0125] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Anaerolineaceae, including Aestuariimicrobium, Arachnia, Auraticoccus, Brooklawnia, Friedmanniella, Granulicoccus, Luteococcus, Mariniluteicoccus, Microlunatus, Micropruina, Naumannella, Propionibacterium, Propionicicella, Propioniciclava, Propioniferax, Propionimicrobium, and Tessaracoccus.

[0126] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus in the family Prevotellaceae, including Paraprevotella, Prevotella, hallella, Xylanibacter, and Alloprevotella.

[0127] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Neocallimastigaceae, including Anaeromyces, Caecomyces, Cyllamyces, Neocallimastix, Orpinomyces, and Piromyces.

[0128] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Saccharomycetaceae, including Brettanomyces, Candida, Citeromyces, Cyniclomyces, Debaryomyces, Issatchenkia, Kazachstania (syn. Arxiozyma), Kluyveromyces, Komagataella, Kuraishia, Lachancea, Lodderomyces, Nakaseomyces, Pachysolen, Pichia, Saccharomyces, Spathaspora, Tetrapisispora, Vanderwaltozyma, Torulaspora, Williopsis, Zygosaccharomyces, and Zygotorulaspora.

[0129] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Erysipelotrichaceae, including Erysipelothrix, Solobacterium, Turicibacter, Faecalibaculum, Faecalicoccus, Faecalitalea, Holdemanella, Holdemania, Dielma, Eggerthia, Erysipelatoclostridium, Allobacterium, Breznakia, Bulleidia, Catenibacterium, Catenisphaera, and Coprobacillus.

[0130] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus in the family Phaeosphaeriaceae, including Barria, Bricookea, Carinispora, Chaetoplea, Eudarluca, Hadrospora, Isthmosporella, Katumotoa, Lautitia, Metameris, Mixtura, Neophaeosphaeria, Nodulosphaeria, Ophiosphaerella, Phaeosphaeris, Phaeosphaeriopsis, Setomelanomma, Stagonospora, Teratosphaeria, and Wilmias.

[0131] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, wherein the microbial product comprises an isolated microbial species selected from a genus of the family Botryosphaeriaceae, including Amarenomyces, Aplosporella, Auerswaldiella, Botryosphaeria, Dichomera, Diplodia, Discochora, Dothidothia, Dothiorella, Fusicoccum, Granulodiplodia, Guignardia, Lasiodiplodia, Leptodothiorella, Leptodothiorella, Leptoguignardia, Macrophoma, Macrophomina, Nattrassia, Neodeightonia, Neofusicocum, Neoscytalidium, Otthia, Phaeobotryosphaeria, Phomatosphaeropsis, Phyllosticta, Pseudofusicoccum, Saccharata, Sivanesania, and Thyrostroma.

[0132] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, the microbial product comprising an isolated microbial species selected from the genera Clostridium, Ruminococcus, Roseburia, Hydrogenoanaerobacterium, Saccharofermentans, Papillibacter, Pelotomaculum, Butyricicoccus, Tannerella, Prevotella, Butyricimonas, Piromyces, Candida, Vrystaatia, Orpinomyces, Neocallimastix, and Phyllosticta. In further embodiments, the disclosure provides a microbial product produced by the methods described herein, the microbial product comprising an isolated microbial species belonging to the family Lachnospiraceae and the order Saccharomycetales. In further embodiments, the disclosure provides a microbial product produced by the methods described herein, the microbial product comprising an isolated microbial species of Candida xylopsoci, Vrystaatia aloeicola, and Phyllosticta capitalensis.

[0133] In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, the microbial product comprising an isolated microbial species selected from Clostridium spp. bacteria, Siccinivibrio spp. bacteria, Caecomyces spp. fungi, Pichia spp. fungi, Butyrivibio spp. bacteria, Orpinomyces spp. fungi, Piromyces spp. fungi, Bacillus spp. bacteria, Lactobacillus spp. bacteria, Prevotella spp. bacteria, Syntrophococcus spp. bacteria, or Ruminococcus spp. bacteria. In some embodiments, the disclosure provides a microbial product prepared by the methods described herein, the microbial product comprising an isolated microbial species selected from a genus of the Lachnospiraceae family.

[0134] In some embodiments, the isolated microbial strain in the product described herein is genetically modified. In some embodiments, the genetically modified or recombinant microbial organism comprises a polynucleotide sequence that does not naturally occur in the microbial organism. In some embodiments, the microbial organism may comprise a heterologous polynucleotide. In further embodiments, the heterologous polynucleotide may be operably linked to one or more polynucleotides that are native to the microbial organism.

[0135] In some embodiments, the heterologous polynucleotide may be a reporter gene or a selectable marker. In some embodiments, the reporter gene may be selected from any of the fluorescent protein family (e.g., GFP, RFP, YFP, etc.), β-galactosidase, or luciferase. In some embodiments, the selectable marker may be selected from neomycin phosphotransferase, hygromycin phosphotransferase, aminoglycoside adenyltransferase, dihydrofolate reductase, acetolactase synthase, bromoxynil nitrilase, β-glucuronidase, dihydrogolate reductase, and chloramphenicol acetyltransferase. In some embodiments, the heterologous polynucleotide may be operably linked to one or more promoters.

[0136] In some embodiments, isolated microorganisms are identified by ribosomal nucleic acid sequences. Ribosomal RNA genes (rDNA's), particularly the small subunit ribosomal RNA genes, i.e., 18S rRNA gene (18S rDNA) for eukaryotes and 16S rRNA (16S rDNA) for prokaryotes, have been the predominant targets for the assessment of types and strains of organisms within microbial communities. However, the large subunit ribosomal RNA gene, 28S rDNA, has also been targeted. rDNA is suitable for taxonomic identification because: (i) it is ubiquitous in all known organisms; (ii) it has both conserved and variable regions; and (iii) there is an exponentially expanding database of sequences available for comparison. In joint analysis of samples, the conserved regions serve as annealing sites for the corresponding universal PCR and / or sequencing primers, while the variable regions can be used for phylogenetic differentiation. Furthermore, the high copy number of rDNA in cells facilitates its detection from environmental samples.

[0137] The internal transcribed spacer (ITS), located between the 18S rDNA and the 28S rDNA, has also been targeted. The ITS is transcribed but spliced ​​before the assembly of the ribosome. The ITS region consists of two highly variable spacers, ITS1 and ITS2, and the inserted 5.8S gene. This rDNA operon occurs in multiple copies in the genome. The ITS region is highly variable since it does not code for ribosomal components. In some embodiments, the unique RNA marker can be an mRNA marker, an siRNA marker, or a ribosomal RNA marker.

[0138] The primary structure of the major rRNA subunit 16S contains a specific combination of conserved, variable, and hypervariable regions that evolve at different rates and enable the resolution of both very ancient lineages, such as domains, and more modern lineages, such as genera. The secondary structure of the 16S subunit contains approximately 50 helices that result in base pairing of about 67% of the residues. These highly conserved secondary structure features are of great functional importance and can be used to ensure positional homology in multiple sequence alignments and phylogenetic analyses. Over the previous decades, the 16S rRNA gene has become the most sequenced taxonomic marker and is the cornerstone for the current systematic classification of bacteria and archaea (Yarza et al. 2014. Nature Rev. Micro. 12:635-45).

[0139] In some embodiments, sequence identity of 94.5% or less for two 16S rRNA genes is strong evidence for different genera, 86.5% or less is strong evidence for different families, 82% or less is strong evidence for different orders, 78.5% is strong evidence for different classes, and 75% or less is strong evidence for different phyla. Comparative analysis of 16S rRNA gene sequences allows the establishment of taxonomic thresholds that are useful not only for the classification of cultured microorganisms, but also for the classification of many environmental sequences. (Yarza et al. 2014. Nature Rev. Micro. 12:635-45).

[0140] Exemplary isolated microorganisms that can be preserved and incorporated into products according to the methods described herein are provided in Table 2 below. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7]

[0141] Microbial ensembles In some aspects, the disclosure provides a microbial product comprising a microbial ensemble produced by the methods described herein and comprising a combination of at least two survival enhancing microorganisms. In certain embodiments, the ensemble of the disclosure comprises two microorganisms, or three microorganisms, or four microorganisms, or five microorganisms, or six microorganisms, or seven microorganisms, or eight microorganisms, or nine microorganisms, or ten or more microorganisms. The microorganisms of the ensemble are different microbial species or different strains of a microbial species.

[0142] As used herein, "microbial ensemble" refers to a composition that includes one or more active microorganisms that do not naturally occur in a naturally occurring environment and / or in a ratio or amount that does not naturally occur. For example, a microbial ensemble (also a synthetic ensemble and / or a bioensemble) or aggregate can be formed from one or more isolated microbial strains together with a suitable medium or carrier. The microbial ensemble can be applied or administered to a target, such as a target environment, population, individual, animal, etc.

[0143] In certain aspects of the present disclosure, the microbial ensemble is or is based on one or more isolated microorganisms that exist as isolated cultures and biologically pure cultures.

[0144] In some embodiments, the present disclosure provides a microbial product produced by the methods described herein and comprising a microbial ensemble, the microbial ensemble comprising at least two isolated microbial species selected from Clostridium spp. bacteria, Succinivibrio spp. bacteria, Caecomyces spp. fungi, Pichia spp. fungi, Butyrivibio spp. bacteria, Orpinomyces spp. fungi, Piromyces spp. fungi, Bacillus spp. bacteria, Lactobacillus spp. bacteria, Prevotella spp. bacteria, Syntrophococcus spp. bacteria, or Ruminococcus spp. bacteria. Exemplary species are provided in Table 2 above.

[0145] In some embodiments, the disclosure provides a microbial product produced by the methods described herein and comprising a microbial ensemble, the microbial ensemble comprising Clostridium spp. comprising a 16S rRNA sequence having at least 97%, 98%, or 99% sequence identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6. In some embodiments, the microbial ensemble comprises Clostridium spp. comprising a 16S rRNA sequence comprising or consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6. In some embodiments, the disclosure provides a microbial product produced by the methods described herein and comprising a microbial ensemble, the microbial ensemble comprising a species from the family Lachnospiraceae comprising a 16S rRNA sequence having at least 97%, 98%, or 99% sequence identity to SEQ ID NO:12. In some embodiments, the microbial ensemble comprises a species from the family Lachnospiraceae comprising a 16S rRNA sequence comprising or consisting of SEQ ID NO:12.

[0146] In some embodiments, the disclosure provides a microbial product produced by a method described herein and comprising a microbial ensemble, the microbial ensemble comprising Succinivibrio spp. comprising a 16S rRNA sequence comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO: 11. In some embodiments, the microbial ensemble comprises Succinivibrio spp. comprising a 16S rRNA sequence comprising or consisting of SEQ ID NO: 11.

[0147] In some embodiments, the disclosure provides a microbial product produced by a method described herein and comprising a microbial ensemble, the microbial ensemble comprising Pichia spp. comprising an ITS sequence comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO: 2. In some embodiments, the microbial ensemble comprises Pichia spp. comprising an ITS sequence comprising or consisting of SEQ ID NO: 2.

[0148] In some embodiments, the disclosure provides a microbial product produced by the methods described herein and comprising a microbial ensemble, the microbial ensemble comprising Bacillus spp. comprising a 16S rRNA sequence comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO:4. In some embodiments, the microbial ensemble comprises Bacillus spp. comprising or consisting of SEQ ID NO:4. In some embodiments, the disclosure provides a microbial product produced by the methods described herein and comprising a microbial ensemble, the microbial ensemble comprising Lactobacillus spp. comprising a 16S rRNA sequence comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9. In some embodiments, the microbial ensemble comprises Lactobacillus spp. comprising a 16S rRNA sequence comprising or consisting of SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9.

[0149] In some embodiments, the disclosure provides a microbial product produced by a method described herein and comprising a microbial ensemble, the microbial ensemble comprising Prevotella spp. comprising a 16S rRNA sequence comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO: 10. In some embodiments, the microbial ensemble comprises Prevotella spp. comprising a 16S rRNA sequence comprising or consisting of SEQ ID NO: 10.

[0150] In some aspects, the disclosure provides a microbial product produced by a method described herein and comprising a microbial ensemble, the microbial ensemble comprising Clostridium butyricum comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO:1, and Pichia kudriazevii comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO:2.

[0151] In some embodiments, the disclosure provides a microbial product produced by the methods described herein and comprising a microbial ensemble, the microbial ensemble comprising Clostridium spp. comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO:5, Clostridium spp. comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO:6, and Lactobacillius spp. comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO:7. In some embodiments, the disclosure provides a microbial product produced by the methods described herein and comprising a microbial ensemble, the microbial ensemble comprising Clostridium spp. comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO:5, and Clostridium spp. comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO:6.

[0152] In some aspects, the disclosure provides a microbial product produced by a method described herein and comprising a microbial ensemble, the microbial ensemble comprising Prevotella spp. comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO:10, Succinivibrio spp. comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO:11, and Lachnospiraceae spp. comprising at least 97%, 98%, or 99% sequence identity to SEQ ID NO:12.

[0153] In some aspects, the disclosure provides a microbial product produced by a method described herein and comprising a microbial ensemble, the microbial ensemble comprising at least two isolated microbial species selected from the genera Clostridium, Ruminococcus, Roseburia, Hydrogenoanaerobacterium, Saccharofermentans, Papillibacter, Pelotomaculum, Butyricicoccus, Tannerella, Prevotella, Butyricimonas, Piromyces, Pichia, Candida, Vrystaatia, Orpinomyces, Neocallimastix, and Phyllosticta.

[0154] microbial strains Microorganisms can be differentiated into genera based on polyphasic taxonomy, which incorporates phenotypic and genotypic data in a consensus classification (Vandamme et al. 1996. Polyphasic taxonomy, a consensus approach to bacterial systematics. Microbiol Rev 1996, 60:407-438). One accepted genotypic method for defining species is based on total genomic relatedness, resulting in a ΔT of less than 5°C under standard conditions. mStrains that share approximately 70% or more relatedness using DNA-DNA hybridization (melting temperature difference between homogeneous and heterogeneous hybrids) are considered members of the same species. Thus, populations that share the above-mentioned 70% threshold can be considered as variants of the same species. Another accepted genotypic method for defining species is to isolate the marker genes of the present disclosure, sequence these genes, and align these sequenced genes from multiple isolates or variants. Microorganisms are considered to belong to the same species if one or more of the sequenced genes share at least 97% sequence identity.

[0155] Microorganisms isolated can be matched to the closest taxon by utilizing the classification tools of the Ribosomal Database Project (RDP) for 16s rRNA sequences and the accessible Nordic ITS Ectomycorrhizal (UNITE) database for ITS rRNA sequences. Examples of microorganisms matched to the closest taxon can be found in Lan et al. (2012. PLOS one. 7(3): e32491), Schloss and Westcott (2011. Appl. Environ. Microbiol. 77(10): 3219-3226), and Koljalg et al. (2005. New Phytologist. 166(3): 1063-1068). 16S or 18S rRNA sequences or ITS sequences are often used to distinguish species and strains, in that if one of the above sequences shares less than a certain percentage of sequence identity with a reference sequence, the two organisms from which the sequences were obtained are said to be of different species or strains. Comparisons may also be made using 23S rRNA sequences against a reference sequence.

[0156] Thus, one may consider microorganisms to be of the same species if they share at least 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity across the 16S or 18S rRNA sequences, or the ITS1 or ITS2 sequences. Further, one may define microbial strains of a species as sharing at least 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity across the 16S or 18S rRNA sequences, or the ITS1 or ITS2 sequences.

[0157] In one embodiment, the microbial strains of the present disclosure include those that contain a polynucleotide sequence that shares at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NOs:1-12. In further embodiments, the microbial strains of the present disclosure include those comprising a polynucleotide sequence that shares at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with any one of SEQ ID NOs:1-12.

[0158] Uncultivable microorganisms often cannot be assigned to a definite species without phenotypic determination, and the microorganism can be given the intragenus designation candidatus, provided that its 16S or 18S rRNA sequences or ITS sequences are consistent with the principle of identity to known species.

[0159] One approach is to look at the distribution of a large number of strains of closely related species in sequence space and identify clusters of strains that are well separated from other clusters. This approach has been developed by using concatenated sequences of multiple core (housekeeping) genes to evaluate clustering patterns and is called multilocus sequence analysis (MLSA) or multilocus sequence phylogenetic analysis. MLSA has been used successfully to explore clustering patterns in large numbers of strains that are assigned to very closely related species by current taxonomic methods, to look at relationships between small numbers of strains within a genus or broader taxonomic group, and to address specific taxonomic questions. More generally, the method can be used to confirm whether bacterial species exist, i.e., whether large populations of similar strains always fall into well-separated clusters, or whether there is a genetic continuum where, in some cases, no clear separation into clusters is observed.

[0160] To make the determination of the genus more accurate, the determination of phenotypic traits, e.g., morphological, biochemical, and physiological characteristics, can be performed for comparison with prototypes of reference genuses. The colony morphology can include color, shape, pigmentation, slime production, etc. The cellular characteristics are described in terms of shape, size, Gram reaction, extracellular material, the presence of endospores, the presence and position of flagella, motility, and inclusion bodies. The biochemical and physiological characteristics describe the growth of the organisms in a range of temperature, pH, salinity, and atmospheric conditions, and growth in the presence of various sole carbon and nitrogen sources. The skilled artisan should be reasonably informed regarding the phenotypic traits that define the genus of the present disclosure.

[0161] In one embodiment, 16S rRNA gene sequences and ITS sequences were used to identify the microorganisms taught herein. It is known in the art that 16S rRNA contains hypervariable regions that can provide species / strain specific signature sequences useful for bacterial identification, and that ITS sequences can also provide species / strain specific signature sequences useful for fungal identification.

[0162] Phylogenetic analyses using rRNA gene and / or ITS sequences are used to define "substantially similar" species within a common genus, and also to define "substantially similar" strains of a given taxonomic species. Furthermore, physiological and / or biochemical properties of isolates can be utilized to highlight both subtle and significant differences between strains that may lead to advantageous behavior in ruminants.

[0163] The compositions of the present disclosure may include combinations of fungal spores and bacterial spores, fungal spores and bacterial vegetative cells, fungal vegetative cells and bacterial spores, fungal vegetative cells and bacterial vegetative cells. In some embodiments, the compositions of the present disclosure include bacteria only in the form of spores. In some embodiments, the compositions of the present disclosure include bacteria only in the form of vegetative cells. In some embodiments, the compositions of the present disclosure include bacteria in the absence of fungi. In some embodiments, the compositions of the present disclosure include fungi in the absence of bacteria.

[0164] Bacterial spores may include endospores and akinetes. Fungal spores may include non-shotspores, shotspores, autospores, immobile spores, zoospores, vegetative spores, megaspores, microspores, meiospores, chlamydospores, uredospores, teliospores, oospores, carpospores, tetraspores, sporangiospores, zygospores, ascospores, basidiospores, ascospores, and ascospores.

[0165] microbial products In some embodiments, the disclosure provides a product comprising a population of viability-enhanced microbial cells prepared and preserved by the continuous preservation methods described herein. In some embodiments, the microbial product prepared by the methods described herein comprises one or more viability-enhanced microorganism(s) and an acceptable carrier. In further embodiments, the viability-enhanced microorganism(s) is encapsulated. In further embodiments, the encapsulated viability-enhanced microorganism(s) comprises a polymer. In further embodiments, the polymer may be selected from a sugar polymer, an agar polymer, an agarose polymer, a protein polymer, a sugar polymer, and a lipid polymer.

[0166] In some embodiments, the acceptable carrier is selected from the group consisting of edible feed grade substances, mineral mixtures, water, glycol, molasses, and corn oil. In some embodiments, the at least two microbial strains forming the microbial ensemble are present in an amount of 10 per gram of the composition. 2 ~10 15 In some embodiments, the composition may be mixed with a feed composition.

[0167] In some embodiments, the microbial product of the present disclosure is administered to an animal. In some embodiments, the composition is administered at least once a day. In further embodiments, the composition is administered at least once a month. In further embodiments, the composition is administered at least once a week. In further embodiments, the composition is administered at least once an hour.

[0168] In some embodiments, administration comprises injection of the composition into the rumen. In some embodiments, the composition is administered anally. In further embodiments, anal administration comprises inserting a suppository into the rectum. In some embodiments, the composition is administered orally. In some aspects, oral administration comprises administering the composition in combination with the animal's feed, water, medication, or vaccination. In some aspects, oral administration comprises applying the composition in a gel or viscous solution to the animal's body parts, and the animal ingests the composition by licking. In some embodiments, administration comprises spraying the composition on the animal, and the animal ingests the composition. In some embodiments, administration occurs every time the animal is fed. In some embodiments, oral administration comprises administering the composition in combination with the animal's feed.

[0169] In some embodiments, the microbial products of the present disclosure include ruminant feeds, such as cereals (such as barley, corn, oats, etc.); starches (such as tapioca); oilseed cakes; and vegetable waste. In some embodiments, the microbial products include vitamins, minerals, trace elements, emulsifiers, flavoring products, binders, colorants, odorants, thickeners, and the like.

[0170] In some embodiments, the microbial products of the present disclosure are solid. When solid compositions are used, it may be desirable to include one or more carrier materials, including, but not limited to, mineral earths, such as silica, talc, kaolin, limestone, chalk, clay, dolomite, diatomaceous earth; calcium carbonate; calcium sulfate; magnesium sulfate; magnesium oxide; plant-derived products, such as grain flour, bark flour, wood flour, and nut shell flour.

[0171] In some embodiments, the microbial products of the present disclosure are liquids. In further embodiments, the liquid comprises a solvent, which may include water or alcohol, and other animal-safe solvents. In some embodiments, the microbial products of the present disclosure comprise a binder, such as an animal-safe polymer, carboxymethylcellulose, starch, polyvinyl alcohol, and the like.

[0172] In some embodiments, the microbial products of the present disclosure include thickening agents such as silica, clay, natural extracts of seeds or seaweed, synthetic derivatives of cellulose, guar gum, locust bean gum, alginates, and methylcellulose. In some embodiments, the microbial products include anti-settling agents such as modified starch, polyvinyl alcohol, xanthan gum, and the like.

[0173] In some embodiments, the microbial products of the present disclosure include colorants that include organic chromophores classified as nitroso, nitro, azo, including monoazo, bisazo, and polyazo, acridine, anthraquinone, azine, diphenylmethane, indamine, indophenol, methine, oxazine, phthalocyanine, thiazine, thiazole, triarylmethane, xanthene. In some embodiments, the microbial compositions of the present disclosure include micronutrients, such as salts of iron, manganese, boron, copper, cobalt, molybdenum, and zinc.

[0174] In some embodiments, the microbial products of the present disclosure include animal-safe virucidal or nematicidal agents. In some embodiments, the microbial compositions of the present disclosure include saccharides (e.g., monosaccharides, disaccharides, trisaccharides, polysaccharides, oligosaccharides, etc.), polymeric saccharides, lipids, polymeric lipids, lipopolysaccharides, proteins, polymeric proteins, lipoproteins, nucleic acids, nucleic acid polymers, silica, inorganic salts, and combinations thereof. In further embodiments, the microbial products include polymers such as agar, agarose, gellite, gellan gum, and the like. In some embodiments, the microbial compositions include plastic capsules, emulsions (e.g., water and oil), membranes, and artificial membranes. In some embodiments, emulsions or linked polymer solutions may include the microbial compositions of the present disclosure. See, for example, Harel and Bennett, U.S. Patent No. 8,460,726 B2, expressly incorporated herein by reference for all purposes.

[0175] In some embodiments, the microbial products of the present disclosure include one or more preservatives. The preservatives may be in liquid or gaseous formulations. Preservatives may be selected from one or more of the following: monosaccharides, disaccharides, trisaccharides, polysaccharides, acetic acid, ascorbic acid, calcium ascorbate, erythorbic acid, isoascorbic acid, erythrobic acid, potassium nitrate, sodium ascorbate, sodium erythorbate, sodium isoascorbate, sodium nitrate, sodium nitrite, nitrogen, benzoic acid, calcium sorbate, ethyl lauroyl arginate, methyl-p-hydroxybenzoate, methylparaben, potassium acetate, potassium benzoate, potassium bisulfite, potassium diacetate, potassium lactate, potassium metabisulfite, potassium sorbate, propyl-p-hydroxybenzoate, propylparaben, sodium acetate, sodium benzoate, sodium bisulfite, sodium nitrite, sodium diacetate, sodium lactate, sodium metabisulfite, the sodium salt of methyl-p-hydroxybenzoate, the sodium salt of propyl-p-hydroxybenzoate, sodium sulfate, sodium sulfite, dithionite. Sodium nitrate, nitrite, calcium propionate, dimethyl dicarbonate, natamycin, potassium sorbate, potassium bisulfite, potassium metabisulfite, propionic acid, sodium diacetate, sodium propionate, sodium sorbate, sorbic acid, ascorbic acid, ascorbyl palmitate, ascorbyl stearate, butylated hydroxyanisole, butylated hydroxytoluene (BHT), butylated hydroxyl anisole (BHA), citric acid, monoglyceride Citrate esters of glycerides and / or diglycerides, L-cysteine, L-cysteine ​​hydrochloride, guaiacum gum, guaiac gum, lecithin, lecithin citrate, monoglyceride citrate, monoisopropyl citrate, propyl gallate, sodium metabisulfite, tartaric acid, tertiary butylhydroquinone, stannous chloride, thiodipropionic acid, dilauryl thiodipropionate, distearyl thiodipropionate, ethoxyquin, sulfur dioxide, formic acid, or tocopherol(s).

[0176] In some embodiments, the microbial products of the present disclosure include bacterial and / or fungal cells in spore, vegetative, and / or lysed cell forms. In one embodiment, the lysed cell forms act as mycotoxin binding agents, e.g., mycotoxins that bind to dead cells.

[0177] In some embodiments, the microbial product is shelf stable in a refrigerator (35-40° F.) for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days. In some embodiments, the microbial product is shelf stable in a refrigerator (35-40° F.) for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 weeks.

[0178] In some embodiments, the microbial product is storage stable at room temperature (68-72°F) or 50-77°F for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days. In some embodiments, the microbial product is storage stable at room temperature (68-72°F) or 50-77°F for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 weeks.

[0179] In some embodiments, the microbial product is storage stable at -23 to 35°F for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days. In some embodiments, the microbial product is storage stable at -23 to 35°F for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 weeks.

[0180] In some embodiments, the microbial product is storage stable at 77-100° F. for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days. In some embodiments, the microbial product is storage stable at 77-100° F. for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 weeks.

[0181] In some embodiments, the microbial product is storage stable between 101-213° F. for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 days. In some embodiments, the microbial product is storage stable between 101-213° F. for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 weeks.

[0182] In some embodiments, the microbial products of the present disclosure comprise a microbial product of about 1-100, about 1-95, about 1-90, about 1-85, about 1-80, about 1-75, about 1-70, about 1-65, about 1-60, about 1-55, about 1-50, about 1-45, about 1-40, about 1-35, about 1-30, about 1-25, about 1-20, about 1-15, about 1-10, about 1-5, about 5-100, about 5-95, about 5-90, about 5-85, about 5-80, about 5-75, about 5-70, about 5-65, about 5-60, about 5-55, about 5-50, about 5-45, about 5-40, about 5-35, about 5-30, about 5-25, about 5-20, about 5-1 5, about 5-10, about 10-100, about 10-95, about 10-90, about 10-85, about 10-80, about 10-75, about 10-70, about 10-65, about 10-60, about 10-55, about 10-50, about 10-45, about 10-40, about 10-35, about 10-30, about 10-25, about 10- 20, about 10-15, about 15-100, about 15-95, about 15-90, about 15-85, about 15-80, about 15-75, about 15-70, about 15-65, about 15-60, about 15-55, about 15-50, about 15-45, about 15-40, about 15-35, about 15-30, about 15-25, about 1 5~20, about 20~100, about 20~95, about 20~90, about 20~85, about 20~80, about 20~75, about 20~70, about 20~65, about 20~60, about 20~55, about 20~50, about 20~45, about 20~40, about 20~35, about 20~30, about 20~25, about 25~100 , about 25~95, about 25~90, about 25~85, about 25~80, about 25~75, about 25~70, about 25~65, about 25~60, about 25~55, about 25~50, about 25~45, about 25~40, about 25~35, about 25~30, about 30~100, about 30~95, about 30~90, about 30~ 85, about 30-80, about 30-75, about 30-70, about 30-65, about 30-60, about 30-55, about 30-50, about 30-45, about 30-40, about 30-35, about 35-100, about 35-95, about 35-90, about 35-85, about 35-80, about 35-75, about 35-70, about 3 5~65, about 35~60, about 35~55, about 35~50, about 35~45, about 35~40, about 40~100, about 40~95, about 40~90, about 40~85, about 40~80, about 40~75, about 40~70, about 40~65, about 40~60, about 40~55, about 40~50, about 40~45,About 45~100, about 45~95, about 45~90, about 45~85, about 45~80, about 45~75, about 45~70, about 45~65, about 45~60, about 45~55, about 45~50, about 50~100, about 50~95, about 50~90, about 50~85, about 50~80, about 50~75, about 50~70, about 50~65, about 5 0~60, approx. 50~55, approx. 55~100, approx. 55~95, approx. 55~90, approx. 55~85, approx. 55~80, approx. 55~75, approx. 55~70, approx. 55~65, approx. 55~60, approx. 60~100, approx. 60~95, approx. 60~90, approx. 60~85, approx. 60~80, approx. 60~75, approx. 60~70, approx. 60~65, approx. 65~1 00, about 65-95, about 65-90, about 65-85, about 65-80, about 65-75, about 65-70, about 70-100, about 70-95, about 70-90, about 70-85, about 70-80, about 70-75, about 75-100, about 75-95, about 75-90, about 75-85, about 75-80, about 80-100, about 80-95 , and are storage stable at refrigerated temperatures (35-40°F), room temperature (68-72°F), 50-77°F, -23-35°F, 70-100°F, or 101-213°F for about 80-90, about 80-85, about 85-100, about 85-95, about 85-90, about 90-100, about 90-95, or 95-100 weeks.

[0183] In some embodiments, the microbial products of the present disclosure are 1-100, 1-95, 1-90, 1-85, 1-80, 1-75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-45, 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-5, 5-100, 5-95, 5-90, 5-85, 5-80, 5-75, 5-70, 5-65, 5-60, 5-55, 5-50, 5-45, 5-40, 5-35, 5-30, 5-25, 5-20, 5-15, 5-10, 10-100, 10-95, 10-90, 10-85, 10-80 , 10~75, 10~70, 10~65, 10~60, 10~55, 10~50, 10~45, 10~40, 10~35, 10~30, 10~25, 10~20, 10~15, 15~100, 15~95, 15~90, 15~85, 15~80, 15~75, 15~70, 15 ~65, 15~60, 15~55, 15~50, 15~45, 15~40, 15~35, 15~30, 15~25, 15~20, 20~100, 20~95, 20~90, 20~85, 20~80, 20~75, 20~70, 20~65, 20~60, 20~55, 20~50, 20~45, 20~40, 20~35, 20~30, 20~25, 25~100, 25~95, 25~90, 25~85, 25~80, 25~75, 25~70, 25~65, 25~60, 25~55, 25~50, 25~45, 25~40, 25~35, 25~30, 30~ 100, 30~95, 30~90, 30~85, 30~80, 30~75, 30~70, 30~65, 30~60, 30~55, 30~50, 30~45, 30~40, 30~35, 35~100, 35~95, 35~90, 35~85, 35~80, 35~75, 35~70, 35~65, 35~60, 35~55, 35~50, 35~45, 35~40, 40~100, 40~95, 40~90, 40~85, 40~80, 40~75, 40~70, 40~65, 40~60, 40~55, 40~50, 40~45, 45~100, 45~95, 45~ 90, 45~85, 45~80, 45~75, 45~70, 45~65, 45~60, 45~55, 45~50, 50~100, 50~95, 50~90, 50~85, 50~80, 50~75, 50~70, 50~65, 50~60, 50~55, 55~100, 55~95,55~90, 55~85, 55~80, 55~75, 55~70, 55~65, 55~60, 60~100, 60~95, 60~90, 60~85, 60~80, 60~75, 60~70, 60~65, 65~100, 65~95, 65~90, 65~85, 65~80, 65~75, 65~70, 70~100, 70~95, 70~90, 70~85, 70~80, 70~75, 7 Storage stable for 5-100, 75-95, 75-90, 75-85, 75-80, 80-100, 80-95, 80-90, 80-85, 85-100, 85-95, 85-90, 90-100, 90-95, or 95-100 weeks at chilled (35-40°F), room temperature (68-72°F), 50-77°F, -23-35°F, 70-100°F, or 101-213°F.

[0184] In some embodiments, the microbial products of the present disclosure are from about 1 to 36, about 1 to 34, about 1 to 32, about 1 to 30, about 1 to 28, about 1 to 26, about 1 to 24, about 1 to 22, about 1 to 20, about 1 to 18, about 1 to 16, about 1 to 14, about 1 to 12, about 1 to 10, about 1 to 8, about 1 to 6, about 1 to 4, about 1 to 2, about 4 to 36, about 4 to 34, about 4 to 32, about 4 to 30, about 4 to 28, about 4 to 26, about 4 to 24, about 4 to 22, about 4 to 20, about 4 to 18, about 4 to 16, about 4 to 14, about 4 to 12, about 4 to 10, about 4 to 8, about 4 to 6, about 6 to 36, about 6 to 34, about 6 to 32, about 6 to 30, about 6 to 2 8, about 6-26, about 6-24, about 6-22, about 6-20, about 6-18, about 6-16, about 6-14, about 6-12, about 6-10, about 6-8, about 8-36, about 8-34, about 8-32, about 8-30, about 8-28, about 8-26, about 8-24, about 8-22, about 8-20, about 8-18, about 8- 16, about 8-14, about 8-12, about 8-10, about 10-36, about 10-34, about 10-32, about 10-30, about 10-28, about 10-26, about 10-24, about 10-22, about 10-20, about 10-18, about 10-16, about 10-14, about 10-12, about 12-36, about 12-34 , about 12-32, about 12-30, about 12-28, about 12-26, about 12-24, about 12-22, about 12-20, about 12-18, about 12-16, about 12-14, about 14-36, about 14-34, about 14-32, about 14-30, about 14-28, about 14-26, about 14-24, about 14- 22, about 14-20, about 14-18, about 14-16, about 16-36, about 16-34, about 16-32, about 16-30, about 16-28, about 16-26, about 16-24, about 16-22, about 16-20, about 16-18, about 18-36, about 18-34, about 18-32, about 18-30, about 18 ~28, about 18~26, about 18~24, about 18~22, about 18~20, about 20~36, about 20~34, about 20~32, about 20~30, about 20~28, about 20~26, about 20~24, about 20~22, about 22~36, about 22~34, about 22~32, about 22~30, about 22~28, about 22-26, about 22-24, about 24-36, about 24-34, about 24-32, about 24-30, about 24-28, about 24-26, about 26-36, about 26-34, about 26-32, about 26-30, about 26-28, about 28-36, about 28-34, about 28-32, about 28-30, about 30-36,It is storage stable at refrigerated (35-40°F), room temperature (68-72°F), 50-77°F, -23-35°F, 70-100°F, or 101-213°F for about 30-34, about 30-32, about 32-36, about 32-34, or about 34-36 months.

[0185] In some embodiments, the microbial products of the disclosure are 1-36, 1-34, 1-32, 1-30, 1-28, 1-26, 1-24, 1-22, 1-20, 1-18, 1-16, 1-14, 1-12, 1-10, 1-8, 1-6, 1-4, 1-2, 4-36, 4-34, 4-32, 4-30, 4-28, 4-26, 4-24, 4-22, 4-20, 4-18, 4-16, 4-14, 4-12, 4-10, 4-8, 4-6, 6-36, 6-34, 6-32, 6-30, 6-28, 6-26, 6-24, 6-22, 6-20, 6-18, 6- 16, 6-14, 6-12, 6-10, 6-8, 8-36, 8-34, 8-32, 8-30, 8-28, 8-26, 8-24, 8-22, 8-20, 8-18, 8-16, 8-14, 8-12, 8-10, 10-36, 10-34, 10-32, 10-30, 10-28, 10-26, 10-24, 10-22, 10-20, 10-18, 10-16, 10-14, 10-12, 12-36, 12-34, 12-32, 12-30, 12-28, 12-26, 12-24, 12-22, 12-20, 12-18, 12-16, 12-1 4, 14-36, 14-34, 14-32, 14-30, 14-28, 14-26, 14-24, 14-22, 14-20, 14-18, 14-16, 16-36, 16-34, 16-32, 16-30, 16-28, 16-26, 16-24, 16-22, 16-20, 16-18, 18-36, 18-34, 18-32, 18-30, 18-28, 18-26, 18-24, 18-22, 18-20, 20-36, 20-34, 20-32, 20-30, 20-28, 20-26, 20-24, 20-22, 22-36, 22- Storage stable at chilled temperatures (35-40°F), room temperature (68-72°F), 50-77°F, -23-35°F, 70-100°F, or 101-213°F for a period of about 34, 22-32, 22-30, 22-28, 22-26, 22-24, 24-36, 24-34, 24-32, 24-30, 24-28, 24-26, 26-36, 26-34, 26-32, 26-30, 26-28, 28-36, 28-34, 28-32, 28-30, 30-36, 30-34, 30-32, 32-36, 32-34, or about 34-36.

[0186] In some embodiments, the microbial product of the present disclosure comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, or 98% relative humidity and any of the disclosed temperatures and / or temperature ranges and time intervals.

[0187] Enclosed Products In some embodiments, the survival rate enhancing microorganism(s) (e.g., microorganisms and / or synthetic microbial compositions) of the present disclosure are encapsulated in an encapsulation composition. The encapsulation composition protects the microorganism from external stressors before entering the gastrointestinal tract of the ungulate. The encapsulation composition further creates an environment that may be beneficial to the microorganism, such as minimizing the oxidative stress of an aerobic environment for anaerobic microorganisms. For encapsulation compositions of microorganisms and methods of encapsulating microorganisms, see Kalsta et al. (US 5,104,662 A), Ford (US 5,733,568 A), and Mosbach and Nilsson (US 4,647,536 A). Additional methods and formulations of synthetic ensembles may include the formulations and methods disclosed in one or more of the following U.S. Patent Nos. 6,537,666, 6,306,345, 5,766,520, 6,509,146, 6,884,866, 7,153,472, 6,692,695, 6,872,357, 7,074,431, and / or 6,534,087, each of which is expressly incorporated herein by reference in its entirety.

[0188] In one embodiment, the encapsulation composition comprises microcapsules having multiple liquid cores encapsulated in a solid shell material. For purposes of this disclosure, the "multiplicity" of cores is defined as two or more.

[0189] The first category of useful fusible shell materials is that of solid fats, including fats that are already of suitable hardness, and animal or vegetable oils that are hydrogenated until their melting points are high enough for the purposes of this disclosure. Depending on the desired process and storage temperature and the specific material selected, the specific fat can be either a normally solid or a normally liquid material. The terms "normally solid" and "normally liquid" as used herein refer to the state of the material at the desired temperature for storing the resulting microcapsules. Since fats and hardened oils do not strictly have melting points, the term "melting point" is used herein to describe the minimum temperature at which the fusible material becomes sufficiently soft or liquid to be effectively emulsified and spray cooled, thereby allowing the shell material to have sufficient integrity to prevent the release of the choline core. "Melting point" is similarly defined herein for other materials that do not have sharp melting points.

[0190] Specific examples of fats and oils useful herein (some of which require hydrogenation) are as follows: animal fats and oils, such as beef tallow, mutton tallow, lamb fat, lard or pork fat, fish oil, and sperm oil; vegetable oils, such as canola oil, cottonseed oil, peanut oil, corn oil, olive oil, soybean oil, sunflower oil, safflower oil, palm oil, linseed oil, tung oil, and castor oil; fatty acid mono- and diglycerides; free fatty acids, such as stearic acid, palmitic acid, and oleic acid; and mixtures thereof. This list of fats and oils is not intended to be exhaustive, but is intended to be illustrative only. Specific examples of fatty acids include linoleic acid, gamma-linoleic acid, dihomo-gamma-linolenic acid, arachidonic acid, docosatetraenoic acid, vaccenic acid, nervonic acid, mead acid, erucic acid, gondonic acid, elaidic acid, oleic acid, palitoleic acid, stearidonic acid, eicosapentaenoic acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, and pentadecaenoic acid. Acids include, but are not limited to, oleic acid, palmitic acid, margaric acid, stearic acid, nonadecylic acid, arachidic acid, heneicosylic acid, behenic acid, tricosylic acid, lignoceric acid, pentacosylic acid, cerotic acid, heptacosylic acid, montanic acid, nonacosylic acid, melissic acid, henatriacontylic acid, racemic acid, silicic acid, gedic acid, ceroplastic acid, hexatriacontylic acid, heptatriacontanoic acid, and octatriacontanoic acid.

[0191] Another category of fusible materials useful for encapsulating the shell material are those of waxes. Representative waxes contemplated for use herein are as follows: animal waxes such as beeswax, lanolin, shell wax, and Chinese insect wax; vegetable waxes such as carnauba, candelilla, bayberry, and sugarcane; mineral waxes such as paraffin, microcrystalline petroleum, ozokerite, ceresin, and montan; synthetic waxes such as low molecular weight polyolefins (e.g., CARBOWAX), and polyol ether esters (e.g., sorbitol); Fischer-Tropsch synthetic waxes; and mixtures thereof. Water-soluble waxes such as CARBOWAX and sorbitol are not contemplated herein if the core is aqueous.

[0192] Still other fusible compounds useful herein are fusible natural resins, such as rosin, balsam, shellac, and mixtures thereof. Various auxiliary materials are contemplated for incorporation into the fusible material according to the present disclosure. For example, antioxidants, light stabilizers, dyes and lakes, fragrances, essential oils, anti-caking agents, fillers, pH stabilizers, sugars (monosaccharides, disaccharides, trisaccharides, and polysaccharides), and the like, can be incorporated into the fusible material in large amounts and do not detract from its usefulness for the present disclosure. The core material contemplated according to some embodiments herein comprises about 0.1% to about 50%, about 1% to about 35%, or about 5% to about 30% by weight of the microcapsule. In some embodiments, the core material contemplated herein comprises about 30% or less by weight of the microcapsule. In some embodiments, the core material contemplated herein comprises about 5% by weight of the microcapsule. Depending on the implementation, the core material may be liquid or solid at the intended storage temperature of the microcapsules.

[0193] The core may include other additives, including edible sugars, such as sucrose, glucose, maltose, fructose, lactose, cellobiose, monosaccharides, disaccharides, trisaccharides, polysaccharides, and mixtures thereof; artificial sweeteners, such as aspartame, saccharin, cyclamates, and mixtures thereof; edible acids, such as acetic acid (vinegar), citric acid, ascorbic acid, tartaric acid, and mixtures thereof; edible starches, such as corn starch; vegetable protein hydrolysates; water-soluble vitamins, such as vitamin C; water-soluble pharmaceuticals; water-soluble nutrients, such as ferrous sulfate; flavorings; salts; monosodium glutamate; antimicrobials, such as sorbic acid; antifungals, such as potassium sorbate, sorbic acid, sodium benzoate, and benzoic acid; food grade pigments and dyes; and mixtures thereof. Depending on the implementation, other potentially useful supplemental core materials are also contemplated.

[0194] In some embodiments, emulsifiers can be utilized to aid in the formation of a stable emulsion. Exemplary emulsifiers include glyceryl monostearate, polysorbate esters, ethoxylated mono- and diglycerides, and mixtures thereof.

[0195] For ease of processing, and in particular to allow good formation of a reasonably stable emulsion, the viscosities of the core and shell materials should be similar at the temperature at which the emulsion is formed. In some embodiments, the ratio of the viscosity of the shell to the viscosity of the core, expressed in centipoise or equivalent units and both measured at the temperature of the emulsion, can be from about 22:1 to about 1:1, from about 8:1 to about 1:1, or from about 3:1 to about 1:1. In some embodiments, a 1:1 ratio can be utilized, although other viscosities can be utilized for various applications, with viscosity ratios within the recited ranges being useful.

[0196] The encapsulation composition is not limited to the microcapsule composition disclosed above. In some embodiments, the encapsulation composition encapsulates the microbial composition in an adhesive polymer that can be natural or synthetic without toxic effects. In some embodiments, the encapsulation composition can be a matrix selected from a sugar matrix, a gelatin matrix, a polymer matrix, a silica matrix, a starch matrix, a foam matrix, etc. In some embodiments, the encapsulating composition may be selected from polyvinyl acetate; polyvinyl acetate copolymers; ethylene vinyl acetate (EVA) copolymers; polyvinyl alcohol; polyvinyl alcohol copolymers; celluloses including ethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, and carboxymethyl cellulose; polyvinylpyrrolidone; polysaccharides including starch, modified starch, dextrin, maltodextrin, alginates, and chitosan; monosaccharides; fats; fatty acids including oils; proteins including gelatin and zein; gum arabic; shellac; vinylidene chloride and vinylidene chloride copolymers; calcium lignosulfonate; acrylic copolymers; polyvinyl acrylate; polyethylene oxide; acrylamide polymers and copolymers; polyhydroxyethyl acrylate, methylacrylamide monomer; and polychloroprene.

[0197] In some embodiments, the encapsulation shell of the present disclosure may be up to 10 μm, 20 μm, 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 110 μm, 120 μm, 130 μm, 140 μm, 150 μm, 160 μm, 170 μm, 180 μm, 190 μm, 200 μm, 210 μm, 220 μm, 230 μm, 240 μm, 250 μm, 260 μm, 270 μm, 280 μm, 290 μm, 300 μm, 310 μm, 320 μm, 330 μm, 340 μm, 350 μm, 360 μm, 370 μm, 380 μm, 390 μm, m, 400μm, 410μm, 420μm, 430μm, 440μm, 450μm, 460μm, 470μm, 480μm, 490μm, 500μm, 510μm, 520μm, 530μm, 540μm, 550μm, 560μm, 570μm, 580μm, 590μm, 60 0μm, 610μm, 620μm, 630μm, 640μm, 650μm, 660μm, 670μm, 680μm, 690μm, 700μm m, 710μm, 720μm, 730μm, 740μm, 750μm, 760μm, 770μm, 780μm, 790μm, 800μm, 8 10μm, 820μm, 830μm, 840μm, 850μm, 860μm, 870μm, 880μm, 890μm, 900μm, 910 μm, 920μm, 930μm, 940μm, 950μm, 960μm, 970μm, 980μm, 990μm, 1000μm, 1010 μm, 1020μm, 1030μm, 1040μm, 1050μm, 1060μm, 1070μm, 1080μm, 1090μm, 110 0μm, 1110μm, 1120μm, 1130μm, 1140μm, 1150μm, 1160μm, 1170μm, 1180μm, 119 0μm, 1200μm, 1210μm, 1220μm, 1230μm, 1240μm, 1250μm, 1260μm, 1270μm, 12 80μm, 1290μm, 1300μm, 1310μm, 1320μm, 1330μm, 1340μm, 1350μm, 1360μm, 1 370μm, 1380μm, 1390μm, 1400μm, 1410μm, 1420μm, 1430μm, 1440μm, 1450μm, 1460μm, 1470μm, 1480μm, 1490μm, 1500μm, 1510μm, 1520μm, 1530μm, 1540μm,1550μm, 1560μm, 1570μm, 1580μm, 1590μm, 1600μm, 1610μm, 1620μm, 1630μm, 1640μm, 1650μm, 1660μm, 1670μm, 1680μm, 1690μm, 1700μm, 1710μm, 1720μm ,1730μm,1740μm,1750μm,1760μm,1770μm,1780μm,1790μm,1800μm,1810μm,1820μm,1830μm,1840μm,1850μm,1860μm,1870μm,1880μm,1890μm,1900μm m, 1910μm, 1920μm, 1930μm, 1940μm, 1950μm, 1960μm, 1970μm, 1980μm, 1990μm, 2000μm, 2010μm, 2020μm, 2030μm, 2040μm, 2050μm, 2060μm, 2070μm, 2080 μm, 2090μm, 2100μm, 2110μm, 2120μm, 2130μm, 2140μm, 2150μm, 2160μm, 2170μm, 2180μm, 2190μm, 2200μm, 2210μm, 2220μm, 2230μm, 2240μm, 2250μm, 226 0μm, 2270μm, 2280μm, 2290μm, 2300μm, 2310μm, 2320μm, 2330μm, 2340μm, 2350μm, 2360μm, 2370μm, 2380μm, 2390μm, 2400μm, 2410μm, 2420μm, 2430μm, 24 40μm, 2450μm, 2460μm, 2470μm, 2480μm, 2490μm, 2500μm, 2510μm, 2520μm, 2530μm, 2540μm, 2550μm, 2560μm, 2570μm, 2580μm, 2590μm, 2600μm, 2610μm, 2 620μm, 2630μm, 2640μm, 2650μm, 2660μm, 2670μm, 2680μm, 2690μm, 2700μm, 2710μm, 2720μm, 2730μm, 2740μm, 2750μm, 2760μm, 2770μm, 2780μm, 2790μm, 2800μm, 2810μm, 2820μm, 2830μm, 2840μm, 2850μm, 2860μm, 2870μm, 2880μm, 2890μm, 2900μm, 2910μm, 2920μm, 2930μm, 2940μm, 2950μm, 2960μm, 2970μm,It may be 2980 μm, 2990 μm, or 3000 μm thick.

[0198] animal feed In some embodiments, the microbial products of the present disclosure are mixed with animal feed. In some embodiments, the animal feed may be in a variety of forms, such as pellets, capsules, granules, powders, liquids, or semi-liquids.

[0199] In some embodiments, the product of the present disclosure is mixed in a feed mill (e.g., Cargill or Western Millin) either alone as a separate premix and / or in a premix with other feed additives such as monensin, vitamins, etc. In one embodiment, the product of the present disclosure is mixed into the feed in the feed mill. In another embodiment, the product of the present disclosure is mixed into the feed itself.

[0200] In some embodiments, the feed may be water, a premix or premixes, forage, feeder, beans (e.g., raw, ground, or ground), grains (e.g., raw, ground, or ground), bean or grain-based oil, bean or grain-based meal, bean or grain-based haylage or silage, bean or grain-based syrup, fatty acids, sugar alcohols (e.g., polyhydric alcohols), commercially prepared compound feeds, and mixtures thereof.

[0201] In some embodiments, forage includes hay, haylage, and silage. In some embodiments, hay includes grass hay (e.g., sudan grass, orchard grass, etc.), alfalfa hay, and clover hay. In some embodiments, haylage includes grass haylage, sorghum haylage, and alfalfa haylage. In some embodiments, silage includes corn, oats, wheat, alfalfa, clover, etc.

[0202] In some embodiments, the premix(s) may be utilized in the feed. The premix may include trace ingredients such as vitamins, minerals, amino acids; chemical preservatives; pharmaceutical compositions such as antibiotics and other drugs; fermentation products, and other ingredients. In some embodiments, the premix is ​​blended into the feed.

[0203] In some embodiments, the feed may include feed concentrates such as soybean hulls, sugar beet pulp, molasses, high protein soybean meal, ground corn, shelled corn, wheat midds, distillers grains, cottonseed hulls, rumen bypass proteins, rumen bypass fats, and grease. For animal feed and animal feed supplements, see Luhman (U.S. Patent Publication No. US20150216817A1), Anderson (U.S. Patent Publication No. US20150216817A1), which may be used in the compositions and methods. See, e.g., U.S. Pat. No. 3,484,243, and Porter and Luhman (U.S. Pat. No. 9,179,694 B2).

[0204] In some embodiments, the feed is produced as a composite, which includes the feed itself, vitamins, minerals, amino acids, and other necessary components in a mixed composition capable of meeting basic dietary needs. Composite feeds may further include premixes. In some embodiments, the microbial composition of the present disclosure may be mixed with an animal feed, a premix, and / or a composite feed. Individual components of the animal feed may be mixed with the microbial composition before feeding to a ruminant. The antimicrobial composition of the present disclosure may be applied in or on a premix, in or on a feed, and / or in or on a composite feed.

[0205] Microbial culture technology Isolation, identification, and culture of the microorganisms of the present disclosure can be performed using standard microbiological techniques, examples of which can be found in: Gerhardt, P. (ed.), Methods for General and Molecular Microbiology. American Society for Microbiology, Washington, DC (1994) and Lennette, EH (ed.), Manual of Clinical Microbiology, Third Edition. American Society for Microbiology, Washington, DC (1980), each of which is incorporated by reference.

[0206] Isolation can be performed by streaking specimens onto solid media (e.g., nutrient agar plates) to obtain single colonies characterized by the phenotypic traits described above (e.g., gram positive / negative, capable of sporulating aerobically / anaerobicly, cell morphology, carbon source metabolism, acid / base production, enzyme secretion, metabolic secretions, etc.) and to reduce the chance of working with contaminated cultures.

[0207] For example, in the case of the microorganisms of the present disclosure, biologically pure isolates can be obtained by repeated subculture of the biological sample, each followed by subculturing followed by streaking onto solid media to obtain individual colonies or colony forming units. Methods for preparing, thawing, and growing freeze-dried bacteria are generally known, for example, in: Gherna, RL and CAReddy. 2007. Culture Preservation, p1019-1033. In CAReddy, TJ Beveridge, JA Breznak, GA Marzluf, TM Schmidt, and LRSnyder, eds. American Society for Microbiology, Washington, DC, 1033 pages (hereby incorporated by reference). Thus, freeze-dried liquid formulations and cultures stored for long periods at -70°C in solutions containing glycerol are contemplated for use in providing the formulations of the present disclosure.

[0208] The microorganisms of the present disclosure can be grown in liquid media under aerobic or anaerobic conditions. The medium for growing the bacterial strains of the present disclosure includes a carbon source, a nitrogen source, and inorganic salts, as well as specially required substances such as vitamins, amino acids, nucleic acids, etc. Examples of suitable carbon sources that can be used for growing the microorganisms include, but are not limited to, starch, peptone, yeast extract, amino acids; sugars such as glucose, arabinose, mannose, glucosamine, maltose, etc.; salts of organic acids such as acetic acid, fumaric acid, adipic acid, propionic acid, citric acid, gluconic acid, malic acid, pyruvic acid, malonic acid, etc.; alcohols such as ethanol and glycerol; fats and oils such as soybean oil, rice bran oil, olive oil, corn oil, and sesame oil. The amount of carbon source added varies depending on the type of carbon source and is usually 1 to 100 g / L. Preferably, glucose, starch, and / or peptone are contained in the medium as the main carbon source at a concentration of 0.1 to 5% (W / V).

[0209] Examples of suitable nitrogen sources that can be used to grow the bacterial strains of the present disclosure include, but are not limited to, amino acids, yeast extract, tryptone, beef extract, peptone, potassium nitrate, ammonium nitrate, ammonium chloride, ammonium sulfate, ammonium phosphate, ammonia, or combinations thereof. The amount of nitrogen source varies depending on the type of nitrogen source and is typically between 0.1 g / L and 30 g / L.

[0210] Inorganic salts, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate, magnesium sulfate, magnesium chloride, ferric sulfate, ferrous sulfate, ferric chloride, ferrous chloride, manganese sulfate, manganese chloride, zinc sulfate, zinc chloride, cupric sulfate, calcium carbonate, sodium chloride, calcium carbonate, sodium carbonate can be used alone or in combination. The amount of inorganic acid varies depending on the type of inorganic salt, and is usually 0.001 g / L to 10 g / L. Examples of specially required substances include, but are not limited to, vitamins, nucleic acids, yeast extract, peptone, meat extract, malt extract, dry yeast, and combinations thereof.

[0211] Cultivation can be carried out at a temperature that allows the growth of the microbial strain, typically between 20°C and 46°C. In some aspects, the temperature range is between 30°C and 39°C. For optimal growth, in some embodiments, the medium can be adjusted to a pH of 6.0 to 7.4. It will be appreciated that commercially available media can also be used to cultivate the microbial strain, such as nutrient broth or nutrient agar available from Difco (Detroit, Michigan). It will be appreciated that the incubation time can vary depending on the type of medium used and the concentration of sugar as the main carbon source.

[0212] In some embodiments, the culture continues for 8-96 hours. The microbial cells thus obtained are isolated using methods well known in the art. Examples include, but are not limited to, membrane filtration and centrifugation. The pH may be adjusted using sodium hydroxide, etc., and the culture may be dried using a freeze dryer until the moisture content is equal to 4% or less. A co-culture of microorganisms may be obtained by growing each of the strains described herein above. In some embodiments, a multi-strain culture of microorganisms may be obtained by growing two or more of the strains described herein above. It will be understood that microbial strains may be cultured together if compatible culture conditions can be used.

[0213] Further Numbered Embodiments Further numbered embodiments of the present disclosure are provided as follows:

[0214] Embodiment 1: A method for improving viability of a microorganism after storage, comprising: subjecting a population of target microbial cells to a first storage challenge to obtain a population of challenge microbial cells; harvesting viable challenge microbial cells from the population of challenge microbial cells; preserving the viable challenge microbial cells to obtain a population of preserved viability-enhanced microbial cells; and preparing a product using the population of preserved viability-enhanced microbial cells.

[0215] Embodiment 2: The method of claim 1, wherein the first preservation challenge comprises freeze-drying, lyophilization, cryopreservation, evaporative preservation, foam preservation, vitrification, glass stabilization, evaporative preservation, spray drying, adsorption drying, extrusion, or fluidized bed drying.

[0216] Embodiment 3: The method of claim 1 or claim 2, wherein preservation of the viable challenge cells comprises freeze-drying, lyophilization, cryopreservation, evaporative preservation, foam preservation, vitrification, glass stabilization, evaporative preservation, spray drying, adsorption drying, extrusion drying, or fluid bed drying.

[0217] Embodiment 4: The method of any one of claims 1 to 3, further comprising subjecting said population of challenged cells to at least one additional storage challenge.

[0218] Embodiment 5: A method for microbial viability enhancement and preservation, the method comprising: subjecting the population of target microbial cells to a first preservation challenge to obtain a first population of challenge microbial cells; harvesting viable challenge microorganisms from the first population of challenge microbial cells to obtain a first population of viable challenge microbial cells; subjecting the first population of viable challenge microbial cells to a second preservation challenge to obtain a second population of challenge microbial cells; harvesting viable challenge microorganisms from the second population of challenge microbial cells to obtain a second population of viable challenge microbial cells; preserving the second population of viable challenge microbial cells to obtain a population of preserved viability-enhanced microbial cells; and using the population of preserved viability-enhanced microbial cells to prepare a product.

[0219] Embodiment 6: The method of claim 5, wherein the first stored challenge and the second stored challenge are of the same challenge type.

[0220] Embodiment 7: The method of claim 5, wherein the first stored challenge and the second stored challenge are different challenge types.

[0221] Embodiment 8: The method of claim 5, wherein the first and second storage challenges are selected from the combinations listed in Table 1.

[0222] Embodiment 9: The method of any one of claims 5 to 8, further comprising subjecting said second population of challenged cells to at least one additional storage challenge.

[0223] Embodiment 10: The method of any one of claims 5 to 9, wherein preserving the second viable challenge cell population comprises freeze-drying, lyophilization, cryopreservation, evaporative preservation, foam preservation, vitrification, glass stabilization, vapor preservation, spray drying, adsorption drying, extrusion drying, or fluid bed drying.

[0224] Embodiment 11: The method according to any one of claims 1 to 10, wherein the population of target microbial cells comprises bacteria of Clostridium spp., Succinivibrio spp., Butyrivibio spp., Bacillus spp., Lactobacillus spp., Prevotella spp., Syntrophococcus spp., or Ruminococcus spp.

[0225] Embodiment 12: The method according to any one of claims 1 to 10, wherein the population of target microbial cells comprises Caecomyces spp. fungi, Pichia spp. fungi, Orpinomyces spp. fungi, or Piromyces spp. fungi.

[0226] Embodiment 13: The method of any one of claims 1 to 10, wherein the population of target microbial cells comprises a species of the family Lachnospiraceae.

[0227] Embodiment 14: The Clostridium spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6; the Succinivibrio spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:11; the Pichia spp. comprises an ITS sequence that comprises at least 97% sequence identity to SEQ ID NO:2; the Bacillus spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:4; the Lactobacillus spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9; the Prevotella spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:10; or the species of the Lachnospiraceae family comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:12. The method according to any one of claims 11 to 13, comprising an rRNA sequence.

[0228] Embodiment 15: The method according to any one of claims 1 to 10, wherein the population of target microbial cells comprises bacteria of Ruminococcus bovis, bacteria of Succinivibrio dextrinosolvens, or fungi of Caecomyces spp.

[0229] Example 16: The method of any one of claims 1 to 10, wherein the population of target microbial cells comprises Clostridium butyricum bacteria, Pichia kudriazevii fungi, Butyrivibio fibrosolvens bacteria, Ruminococcus bovis bacteria, or Succinivibrio dextrinosolvens bacteria.

[0230] Embodiment 17: A product prepared by the method of any one of claims 1 to 16, comprising a population of preserved, viability-enhanced microbial cells.

[0231] Embodiment 18: The product of claim 17, wherein the population of preserved viability-enhancing microbial cells comprises Clostridium spp. bacteria, Succinivibrio spp. bacteria, Caecomyces spp. fungi, Pichia spp. fungi, Butyrivibio spp. bacteria, Orpinomyces spp. fungi, Piromyces spp. fungi, Bacillus spp. bacteria, Lactobacillus spp. bacteria, Prevotella spp. bacteria, Syntrophococcus spp. bacteria, Ruminococcus spp. bacteria, or species of the Lachnospiraceae family.

[0232] Embodiment 19: said Clostridium spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6; said Succinivibrio spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:11; said Pichia spp. comprises an ITS sequence that comprises at least 97% sequence identity to SEQ ID NO:2; said Bacillus spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:4; said Lactobacillus spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:7, SEQ ID NO:8, or SEQ ID NO:9; said Prevotella spp. comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:10; or said species of the Lachnospiraceae family comprises a 16S rRNA sequence that comprises at least 97% sequence identity to SEQ ID NO:12. 20. The article of manufacture of claim 18, comprising an rRNA sequence.

[0233] Incorporation by Reference All references, articles, publications, patents, patent publications, and patent applications cited herein are incorporated by reference in their entirety for all purposes. However, mention of any references, articles, publications, patents, patent publications, and patent applications cited herein is not, and should not be construed as, an admission or in any manner suggestion that they constitute available prior art or form part of the common general knowledge in any country in the world. EXAMPLES

[0234] The present disclosure is further illustrated by reference to the following experimental data and examples, however, it should be noted that these experimental data and examples, like the above-mentioned embodiments, are illustrative and should not be construed as limiting the scope of the present disclosure in any way.

[0235] Example 1 - Preservation by Vapor Challenge and Recovery Protocol The following protocol describes methods and reagents for sequential application of Preservation by Vaporization (PBV) to produce preserved bacterial compositions.

[0236] First, an aliquot of a glycerol stock of a Research Cell Bank (RBC) is streaked onto a growth plate. After an appropriate incubation time, a single colony is selected and used to inoculate a seed tube of tryptic soy broth. The seed tube inoculum is cultured to allow for bacterial expansion, and the expanded bacterial culture is then used to inoculate the main fermentation culture. Bacterial cells are cultured to mid-stationary phase in the main fermentation culture. A sugar load of 5% w / v is included as needed. After 40 hours, cells are harvested and combined with a storage solution to obtain a storage mixture. Exemplary storage solutions are provided below in Tables 3A-3C. Each strain was diluted 10-fold in the storage mixture (100 μL of culture with 900 μL of storage solution). [Table 3A] [Table 3B] [Table 3C]

[0237] To determine the colony forming units (CFU) of the cultures, three 100 μL aliquots from each stock mixture were kept in 96-well plates. For CFU determination, each aliquot was serially diluted 10-fold in PBS and 5 μL of each dilution was spotted onto a plate to determine the CFU.

[0238] For storage, 100 μL of each storage mixture was dispensed into 2 mL serum vials, which were then sealed with lyophilization caps and the vials were placed in aluminum lyophilization blocks. The vials were frozen at -80°C for at least 1 hour, and then the vials in the aluminum blocks were transferred to the lyophilization apparatus. The lyophilization caps were changed to the open position and the following lyophilization program was run: (a) Freeze at -17℃ and normal pressure for 30 minutes. (b) Freeze at -17°C and 1000 mTorr for 15 minutes. (c) Freeze at -17°C and 300 mTorr for 15 minutes. (d) Incubate at 30°C and 300 mTorr for 24 hours. (e) Incubate at 40°C and 300 mTorr for 24 hours. (f) Hold at 25°C.

[0239] Alternative freeze-drying protocols, such as freezing at temperatures between -20°C and 0°C at vacuum pressures below 1000 mTorr (e.g., 900 mTorr, 800 mTorr, 700 mTorr, etc.), may also be used. The primary drying step may involve incubation at a given vacuum pressure level, at a temperature between 10°C and 30°C. The secondary drying step may involve incubation at a higher temperature than that used during primary drying at the same vacuum level.

[0240] All vials are then removed from the lyophilizer and rehydrated as follows. (a) 1 mL of sterile PBS was added to each vial (essentially a 10x dilution of the original stock mixture) and reconstituted by gently pipetting up and down. This mixture was then further diluted 6 logs (relative to all dilutions of E-07) and a 5 μL aliquot of each vial was spot plated for CFU determination. (b) Streak another aliquot of the reconstituted PBV product onto a plate as the starting plate (the "rescue" plate) for subsequent reinoculation.

[0241] Second and third rounds of PBVs are then performed according to the protocol above, using the "rescue" plate as the initial source of bacteria for inoculating the seed tubes.

[0242] Example 2: Serial conservation challenge of Rumniococcus bovis To improve yields through the continuous preservation process, R. bovis (ASCUSDY10) was subjected to a series of preservation challenges and recovery. Following the protocol described in Example 1, R. bovis was subjected to three rounds of preservation by vaporization (PBV) challenge. The results of rounds 1-3 for ASCUSDY10 are presented below in Table 4. As shown, there was a dramatic increase in the % survival of colony forming units (CFU) / mL of DY10 from round 1 (RCB) to round 2 (Rescue 1). [Table 4]

[0243] The genomes of the ASCUSDY10 RCB and round 3 isolates were sequenced to determine any genomic changes as a result of serial passaging. DNA was isolated from R. bovis using the Powersoil Pro kit. Short-read sequencing libraries were prepared from isolated DNA using the Nextera XT kit (Illumina, San Diego, CA) according to the manufacturer's recommended protocol. Libraries were sequenced on an Illumina MiSeq (1x300bp). Reads were mapped to the reference genome using bowtie2 (Langmead B, Salzberg S. (2012) Fast Sequence Analysis). Gapped-read alignment with Bowtie 2. Nature Methods. 9:357-359) and breseq were used to analyze mutations (Deatherage DE, Barrick JE. (2014) Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq. Methods Mol. Biol. 1151:165-188).

[0244] A summary of the mutations is presented in Table 5 below. Mutations 7 and 8 are silent mutations and are unlikely to have a significant effect. Mutations 2, 3, 5, and 6 affect either integrase or transposase and are unlikely to affect storage resistance. Mutation 1 may be the key mutation that leads to improved storage resistance of ASCUSDY10. It occurs 4 bp upstream of GalR-LacI, the galactose operon repressor. This key protein represses the transcription of many genes associated with carbohydrate uptake and metabolism. As uptake of cryoprotectants, often in the form of non-reducing sugars, is a key step in storage resistance, changes in the regulation of sugar uptake may lead to dramatic improvements in storage resistance. Phosphomannomutase may provide another key mutation that likely disrupts the metabolism of storage sugars and allows for intracellular accumulation. [Table 5]

[0245] Example 3: Succinivibrio dextrinosolvens serial conservation challenge S. dextrinosolvens (ASCUSBF53) was subjected to a PBV challenge as described in Example 1. The results of rounds 1-3 for ASCUSBF53 are presented below in Table 6. As shown, the preservative challenge increased both the % PBV survival and the maximum culture titer achieved in the initial culture. [Table 6]

[0246] Example 4: Cryopreservation of Caecomyces spp. To select populations more tolerant to cryogenic storage at -80°C, Caecomyces spp. (ASCUSDY30) were subjected to a series of cryopreservation challenges and recovery. ASCUSDY30 was cultured in a modified version of medium C without Caecomyces spp. rumen fluid and 1% (w / v) glucose (Solomon et al., (2016) Early-branching gut fungi possess a large, comprehensive array of biomass-degrading enzymes. Science. 351:1192-1195). Cultures were grown for 72 h before harvesting by centrifugation at 4,000xg for 10 min at 4°C. Prior to freezing at -80°C, cultures were resuspended in an anaerobic storage solution consisting of 5% sorbitol and 15% sucrose. Frozen cultures were assessed for survival by the TFU enumeration method using roll tubes as previously described for anaerobic fungi (Joblin 2013). K. (1981) Isolation, Enumeration, and Maintenance of Rumen Anaerobic Fungi in Roll Tubes. Applied and Environmental Microbiology. 42:1119-1122).

[0247] As shown in Table 7, the initial population had a viability of thallus forming units (TFU) / mL below the detection limit of the assay. After recovery from this population and rechallenge, the TFU / mL of the remaining population was at least 10-fold higher than in the first round. [Table 7]

Claims

[Claim 1] The invention described in this specification.